BMJ Open

Realist review of COVID-19 vaccine acceptance in the general population and marginalized communities from high income countries

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2024-084560
Article Type:	Original research
Date Submitted by the Author:	22-Jan-2024
Complete List of Authors:	Gonzalez-Jaramillo, Nathalia; University of Bern, ISPM Abbühl, Dominik; University of Bern, ISPM; University of Bern, Faculty of Medicine Roa-Díaz, Zayne; University of Bern Kobler-Betancourt, Cristopher; University of Bern Frahsa, Annika; University of Bern
Keywords:	COVID-19, Meta-Analysis, Vaccination

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Realist review of COVID-19 vaccine acceptance in the general population and marginalized communities from high income countries

Gonzalez-Jaramillo Nathalia, MD,PhD,[1] Abbühl Dominik, MD,[1,2] Roa-Díaz Zayne Milena, RN,PhD,[3] Kobler-Betancourt Cristopher, [1] Frahsa Annika, PhD.[1]

1 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

2 Faculty of Medicine, University of Bern, Bern, Switzerland.

3. Medical Library, University library of Bern, University of Bern, Bern, Switzerland

Word count:

Abstract word count: 336

Declaration of funding

Conflicts of interest / financial disclosures: The authors have no conflicts of interest to declare that are relevant to the content of this article.

Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination plans of our research

Acknowledgments:

We thank the Lindenhof Foundation for their financial support of our research group.

Corresponding author / Reprint requests:

Annika Frahsa. University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland. annika.frahsa@unibe.ch

Institute of Social and Preventive Medicine, University of Bern, Switzerland.

Mittelstrasse 43

3012 Bern, Switzerland

Direct dial: +41 31 684 56 79

ORCIDs:

Nathalia Gonzalez: 0000-0003-4975-4439

Annika Frahsa: 0000-0002-0207-3989

Key Points

Question: What is the difference between predicted vaccination willingness before roll-out and real-world vaccine uptake among the general population and marginalized groups from high income countries?

Findings: In this realist systematic review and meta-analysis that included 18 high income countries, the pooled proportion of vaccination willingness before and after roll-out was 67% versus 73%. The pooled proportion of vaccination willingness among people from diverse marginalized groups was 52%.

Meaning: Limited real-world evidence about vaccine uptake among groups experiencing disadvantage in high income countries is a call to action. Context-specific actions are required to promote vaccine uptake among marginalized groups.

Abstract

Importance

Since late June 2023, there has been a steady increase in reported hospitalizations and deaths from SARS-CoV2. To date, no data comparing the estimated uptake with the real-world statistics of vaccine uptake in the general population and in marginalized communities exist.

Introduction

High-income countries (HIC) achieved success vaccinating their populations against COVID-19, yet some historically, socially, or economically marginalized groups, were possibly left behind in HIC for complex reasons. Local vaccine access barriers and hesitancy possibly explain differences in uptake within and among countries. However, access barriers and vaccine hesitancy share common pathways, which complicates disentangling their effects in vaccination uptake.

Objective

We compared vaccination willingness before roll-out and one-year post-rollout uptake among the general population and disproportionately affected groups in HIC.

Methods

We conducted a quantitative realist synthesis on the prevalence of vaccine acceptance of general populations from HIC. We defined *vaccination willingness* as the proportion of participants willing or intending to receive vaccines prior to availability. We defined vaccine uptake as the real proportion of the population with

complete vaccination as reported by each country until November 2021. We pooled prevalence of vaccination willingness and vaccine uptake using random effects models. We reported our findings according to the statement on preferred reporting items for systematic reviews and meta-analyses.

Results

We included data from 62 studies and 18 HIC. For studies conducted among general populations, the proportion of vaccination willingness was 67% [95% confidence interval (CI) 62%–72%]. In real-world settings, the overall proportion of vaccine uptake among those countries was 73% (CI 69%–76%). The summary proportion of vaccination willingness among people from diverse under-resourced groups was 52% (95% CI 0.46–0.57). However, real-world evidence about vaccine uptake among groups experiencing disadvantage was limited.

Conclusion and Relevance

Our review emphasizes the importance of real-world data for assessing vaccine acceptance and particularly the need for more specific real-world statistics on vaccine uptake among under-resourced communities, disproportionately affected groups, and historically, socially, or economically marginalized groups, as well as the importance of context-specific actions to promote vaccine uptake.

Strengths and limitations of this study

- To our knowledge, this is the first systematic and realist review comparing vaccination willingness from studies and vaccine uptake using real-world data.
- Official country-level reports about vaccine uptake among under-resourced communities was limited so we could not compare vaccination willingness with real-world vaccine uptake statistics among specific groups.

Introduction

Cumulative excess death from the coronavirus disease (COVID-19) pandemic made it a leading global cause of death between 2020–2021.[1] Universal vaccination played a significant role transitioning into post-pandemic life.[2] COVID-19 vaccines were developed and authorized in record time; as of April 2023, 70% of the world population received at least one COVID-19 vaccine dose. However, vaccine uptake is

complicated; it involves more than simply making vaccines available. For instance, inequitable vaccine distribution possibly contributes to the 2.8-fold difference in vaccine coverage between high- and low-income countries.[3] Whereas vaccine uptake in high-income countries (HIC) was 81%, vaccine uptake in low-income countries (LIC) was 29%.[4]

Countries with strong public health systems and economic resources achieved some early success vaccinating populations, yet people from historically, socially, or economically marginalized groups, such as people who experience homelessness, people from ethnic and racial minorities, as well as people with immigration or refugee experience, possibly remained unvaccinated for complex reasons. Regarding vaccination willingness and uptake among people from ethnic minority groups, Raizai et al.[5, 6] identified several structural aspects resulting from a mistrust of government and public health bodies: systemic racism and discrimination at societal and healthcare system levels, histories of unethical studies, as well as underrepresentation of people from ethnic and racial minority groups in health, drug, and vaccine trials. Distrust in medical institutions from inappropriate care and mistreatment also impacted vaccination willingness among people from socially or economically marginalized groups, such as members of indigenous communities or racial minority groups as well as among incarcerated individuals. [7, 8, 9]

Additionally, local barriers to access vaccinations and individual vaccine hesitancy played roles explaining vaccine uptake differences within and among countries.[3] Notwithstanding, structural access barriers and individual vaccine hesitancy possibly share common pathways, which complicates disentangling their effects in vaccination uptake.[10] For instance, in a systematic review of barriers, facilitators, and vaccine hesitancy with included studies about mainly HIC, they found

individuals from minority ethnic groups concurrently experience more access barriers along with higher vaccine hesitancy and lower vaccine uptake when compared with individuals from majority ethnic groups and non-migrants.[11] Therefore, a debate is ongoing about the true proportion of hesitancy and vaccine refusal among unvaccinated individuals in HIC. Although individual vaccination willingness is not under discussion, understandings about vaccination willingness and vaccine uptake possibly inform health policies more reliably, identify access barriers to vaccines, facilitate vaccination campaign planning, and enhance uptake, eventually.

Generally, marginalization and vaccine uptake in HIC has been scarcely described in the literature. We performed a realist synthesis to evaluate COVID-19 vaccine acceptance and its determinants among people from under-resourced communities and disproportionately affected groups in HIC. We compared data collected from a specific systematic review with real-world statistics to study the general evolution of vaccination rates—from hypothetical acceptance before the widespread rollout of vaccination programs—until December 2021, one year after the first vaccine was available and when presumably, most HIC populations could be vaccinated. In addition, we compared hypothetical vaccination willingness between the general population and under-resourced communities and disproportionately affected groups in HIC.

Methods

Study design and sources of data

We conducted a quantitative realist synthesis on the prevalence of vaccine acceptance among the general population from HIC. We followed the realist and meta-narrative evidence syntheses (RAMESES) quality and publication standards and reporting guidelines.[12] We also report our findings according to the statement on

preferred reporting items for systematic reviews and meta-analyses[13] (PRISMA). We defined *vaccination willingness* as the proportion of participants willing or intending to receive a vaccine before vaccines were available. We defined *vaccine uptake* as the real proportion of the population with complete vaccination as reported by each country until November 2021.

A medical information specialist searched for surveys investigating COVID-19 vaccine attitudes among adult populations from HIC before COVID-19 vaccine roll-out. We used the World Bank database to classify countries of origin according to income at the time of data collection [US$12,536 or more gross national income (GNI) per capita in 2019]. We defined the study to include surveys reporting quantitative data on populations willing to be vaccinated when vaccines became available. We included surveys meeting the following criteria: 1) conducted in 2020–2021 among adult populations before vaccine rollout campaigns; 2) reported prevalence of vaccination willingness via questionnaires; 3) peer-reviewed; 4) performed probabilistic sampling; and 5) reported results for general populations and/ or under-resourced communities and disproportionately affected groups.

We excluded studies of unrepresentative participants from general populations, such as people with particular conditions or health statuses—like people with diabetes or pregnant people—or particular occupations—like health care workers or university students. We excluded articles with incomplete information, systematic reviews and meta-analyses, and reports from meetings or congresses.

We provide details for our search strategy, study selection, and data extraction methods in Supplementary section 1. When multiple records included data from the same country, we extracted data from all of them and calculated country-specific

pooled prevalence and used the pooled prevalence as the value to compare further with real-world statistics of vaccine uptake.

Study outcomes

For each country, outcomes of interest included 1) the proportion of people willing to be vaccinated according to results of the systematic review (primary outcome: vaccination willingness/acceptance); and 2) the proportion of vaccinated people according to the real-world data statistics (secondary outcome: vaccine uptake).

Data selection and extraction

Two reviewers independently screened all records and verified included and excluded studies by using REDCap (Vanderbilt University, Nashville, TN, USA). We report identification, exclusion, and inclusion of studies in the Figure S1 flow diagram. One reviewer extracted data using a pre-piloted extraction form, and a second reviewer verified the extracted data. Extracted variables included, yet were not limited to sample size, study design, publication date, survey date, country and study population composition, community type, age, vaccine hesitancy, vaccine acceptance, and vaccine refusal (Supplementary section 1.d). We extracted all proportions as reported. For the realist synthesis, we obtained available country-specific data from multiple sources.[14, 15] We provide sources of information and definitions for country-specific variables in Supplementary section 1.d.

Potential bias assessment

Two independent reviewers assessed the risk of bias for each study using the checklist for prevalence studies from Hoy et al; we assessed each question independently and calculated scores, as recommended by checklist developers.[16] However, we did not use total scores in analyses. Instead, we grouped questions into

categories according to the bias domain they addressed.[17] We analyzed risk of selection bias and risk of nonresponse bias as potential sources of heterogeneity among studies. We provide potential bias assessment results in Supplementary section 2.Table S1.

Statistical analysis

Data synthesis

We estimated the pooled prevalence of vaccination willingness and 95% confidence intervals (CI) using random effects models. We used the 'metaprop' function from the 'meta' package in R (version 3.5.1) to synthesize and display findings from included studies in forest plots. For overall summary estimates, we calculated prediction intervals to represent the likely range of proportions obtained in subsequent studies conducted in similar settings.[18] We quantified statistical heterogeneity using the I^2 statistic. Heterogeneity was classified according to the most recent version of the Cochrane Handbook: 0–40% might not be important; 30–60% may represent moderate heterogeneity; 50–90% may represent substantial heterogeneity; 75– 100% considerable heterogeneity. However, in meta-analyses of prevalence, heterogeneity according to the I^2 statistic is expected to be substantial and possibly not discriminative.[19] Therefore, we also calculated prediction intervals to describe the expected range of estimates.

Sensitivity analyses

We performed sensitivity analyses. First, we used the influence function in the 'metafor' package to compute outliers and influential case diagnostics, including externally standardized residuals and leave-one-out estimates of heterogeneity. Second, we investigated the impact of selection bias as a potential source of heterogeneity by means of meta-regression.

Real-world data analysis

After synthesizing information from included studies, we compared results for each country with real-world data statistics concerning vaccination uptake. In addition, we identified how different country characteristics and policies (Supplementary section 3, Table S2) in each country could be associated with vaccination uptake. Specifically, we selected four components to examine separately: percentage of populations older than 65 years; social spending as a percentage of gross domestic product (GDP); healthcare spending as a percentage of GDP; and stringency index (Oxford COVID-19 Government Response Tracker index) at the start date of vaccine rollout campaigns in each country since we thought them most likely associated with vaccine uptake among general populations.[14]

Results

After deduplication, we identified 3349 potentially relevant citations. After initial screening based on titles and abstracts, we selected full texts of 214 articles for detailed evaluation (Figure S1). After full-text assessment, we excluded 152 citations. We provide the complete list of excluded references and reasons for exclusion in the Supplementary section 1c. We included the remaining 62 articles that reported vaccination willingness before vaccine rollout at the country-level.

General characteristics of included studies.

We provide detailed characteristics of included studies in Table 1. Overall, studies included 299,769 individuals from 18 HIC. Among the 62 included references, 45 studies reported results for general populations and 17 studies reported results for at least one under-resourced community or disproportionately affected group. We calculated the weighted average of exported mean ages from each study; the mean age was 47.5 years. The proportion of women ranged from 16% to 93% among studies

including patients from both sexes. Two studies reported including only men.[20, 21] Study sample sizes conducted among general populations ranged from 316 to 63,266 and study sample sizes conducted among under-resourced communities or disproportionately affected groups ranged from 83 to 18,474.

Since reporting vaccination willingness via questionnaire was an inclusion criteria, all studies used validated questionnaires or questionnaires developed specifically for studies.

General characteristics of the included countries

We present detailed characteristics of included countries in Table S2. Country populations ranged between 2.6 million (Qatar) and 332 million (United States). Median population was 11.1 million [interquartile range (IQR): 7.9–67]. Median percentage of populations older than 65 years was 19 (IQR: 16.8–22.2), and median value for life expectancy was 81.5 years (IQR: 81–83). With respect to economic indicators related to public policy, median social spending as a percentage of GDP was 25 (IQR: 18–29); median healthcare spending as a percentage of GDP was 10.3 (IQR: 8.7–11.3). We determined two median indicators of inequality: poverty gap 0.29 (IQR: 0.26–0.33) and gender wage gap 15 (IQR: 6–19), respectively.

Proportion of people from general populations reporting vaccination willingness before vaccine rollout

Among general populations, the summary proportion of vaccination willingness (Figure 1) was estimated across all study settings as 67% (95% CI 61%–72%, 45 studies). Forty-five studies reported vaccine acceptance among general populations: Australia (3 studies);[22-24] Austria (1);[25] Canada (2);[26, 27] Croatia (1);[28] Denmark (1);[29] France (5);[30-34] Germany (1);[35] Greece (1);[36] Ireland (1);[37] Israel (1);[38] Italy (4);[39-42]

Japan (5);[43-47] Portugal (1);[48] Qatar (1);[49] Switzerland[76] (1); United Kingdom (7);[50-56] and United States (9).[57-65]

Proportion of people from under-resourced communities or disproportionately affected groups reporting vaccination willingness before vaccine rollout

The summary proportion of vaccination willingness for studies conducted among people from socially, economically, or historically marginalized groups (Figure 2) was estimated as 52% (95% CI 0.46–0.57, 17 studies). Seventeen studies reported vaccine acceptance among people experiencing homelessness (4);[66-69] people using illicit and unprescribed drugs (2);[70,71] lesbian, gay, bisexual, and transgender populations (3);[21,72,73] incarcerated populations (2);[20, 74] refugee and undocumented migrant populations (2);[75, 76] an indigenous population (1);[9] a rural community (1);[77] a Latino population (1);[78] and a Black American population (1).[7] In the cumulative meta-analysis from sensitivity analyses, we found a trend towards acceptance according to dates of data acquisition ranging from 32% in early pandemic stages to 52% during late pandemic stages before vaccine rollout (Supplementary section 5.c)

Proportion of vaccine uptake from real-world country statistics one year after vaccine rollout

The summary proportion of vaccine uptake from included countries was estimated as 73% (95% CI 0.69–0.76, 18 countries). In general, the proportion of vaccine uptake for each country was higher than vaccination willingness before vaccine rollout (Supplemental material, Table S3), except for Croatia (-15%), Denmark (-3%), and the United States (-8%). In the cumulative meta-analysis, we did not observe an effect from date of vaccine approval on vaccine uptake at the end of 2021 (Supplementary section 6). However, in meta-regression analyses (Supplementary section 6. Sensitivity analyses) vaccine uptake increased according to the proportion

of the population older than 65 years [odds ratio (OR)=1.8, 95%CI 1.04–3.1] and decreased at higher stringency index values (OR=0.8, 95%CI 0.69–0.94).

Discussion

Main findings

Our realist synthesis involves data from 62 studies and 18 countries; we contribute to knowledge about the prevalence of vaccine acceptance among general populations and people from under-resourced communities, disproportionately affected groups, and historically, socially, or economically marginalized groups. Additionally, we compared proportions of expected vaccine uptake from studies conducted before vaccines were available with the real uptake from the end of December 2021. To our knowledge, ours is the first systematic and realist review comparing vaccination willingness and vaccine uptake using real-world statistics among general populations with people from under-resourced communities or disproportionately affected groups in HIC.

Included countries comprised 70% of HIC populations included in our study. Most countries had higher vaccine uptake when compared with vaccination willingness as reported by the studies conducted before vaccine rollout. For all studies among general populations, the proportion of vaccination willingness was 67% (95% CI 62%–72%). In real-world settings, the overall proportion of vaccine uptake among countries was 73% (CI 69%–76%). However, study limitations prevented exploring possible explanations for lower-than-expected rates of vaccine uptake in Croatia, Denmark, and the United States.

The summary proportion of vaccination willingness among under-resourced communities, disproportionately affected groups, and historically, socially, or

economically marginalized groups was 52% (95% CI 0.46–0.57). A few studies reported vaccine uptake and showed lower vaccine uptake, such as a study among healthcare workers from ethnic minority groups in the United Kingdom compared with White healthcare workers,[79] as well as a federated analysis of patient primary care records in the United Kingdom [80] finding lower uptake by ethnicity (Black 68%, White 96%) and to a lower degree, by deprivation (most deprived 91%, least deprived 97%).

However, official country-level reports about vaccine uptake among under-resourced communities and disproportionately affected groups in diverse perspectives was too limited so we could not compare vaccination willingness with real-world vaccine uptake statistics among specific groups.

Findings in context

The proportion of vaccination willingness among people from under-resourced communities, disproportionately affected groups, and historically, socially, or economically marginalized groups was consistently lower than the proportion of vaccination willingness among people from populations in total. Existing evidence suggest people from ethnic and racialized minority groups[7] and indigenous communities reasonably distrust medical institutions from experiences of differential care and mistreatment.[8, 9] Mistrust of institutions and governments was reported as the most common reason to delay vaccine uptake among incarcerated people.[7,8,9,74] Experiences of discrimination, stigma, and barriers to access were reported as possible explanations for lower prevalence of vaccine acceptance among people from sexual and gender minority groups.[81]

Recent evidence provides initial insights about overcoming barriers to vaccination uptake. For instance, multi-component interventions with tailored communication of risks of remaining unvaccinated and benefits of becoming

vaccinated,[82] community-based action and engagement of religious and community leaders, dialogue to understand reasons for mistrust in government and public health bodies, as well as well as provision of access to convenient vaccination in collaboration with community-based and trusted health institutions.[83]

We suggest future studies compare trajectories of vaccination willingness with vaccine uptake among under-resourced communities, disproportionately affected groups, and historically, socially, or economically marginalized groups. We also recommend future research link findings of trajectories with context-specific actions to address barriers to vaccine uptake among people from under-resourced communities, disproportionately affected groups, and historically, socially, or economically marginalized groups. Ultimately, more research is needed to better understand vaccine uptake and interactions between barriers, unwillingness, hesitancy, postponement, or other unknown aspects driving vaccine uptake. The identification of necessary adjustments needed to improve vaccination uptake among different groups may inform future vaccination programs.

Strengths and limitations

Studies reporting prevalence served as important sources of evidence during the COVID-19 pandemic and helped researchers understand factors related to the disease and inform policies. However, prevalence estimates from individual studies and pooled prevalence estimates from our meta-analyses may have been affected by selection and reporting biases.[17] However, our inclusion criteria attempted to reduce such risks of bias, and we performed multiple sensitivity analyses that provided insights into possible sources of heterogeneity. In the specific context of COVID-19 vaccine acceptance, the fact that countries have reporting systems in place to keep

population-based statistics made it possible to assess the real-life counterpart of the studies.[84]

Conclusion

Our systematic and realist review highlights COVID-19 vaccine uptake in HIC generally exceeded expressed vaccination willingness before vaccine rollout and vaccination willingness tended to be lower among under-resourced communities, disproportionately affected groups, and historically, socially, or economically marginalized groups when compared with total populations living in HIC. Our review emphasizes the importance of real-world data for assessing vaccine acceptance and particularly the need for more specific real-world statistics on vaccine uptake among under-resourced communities, disproportionately affected groups, and historically, socially, or economically marginalized groups, as well as the importance of context-specific actions to promote vaccine uptake.

References

1. Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. JAMA 2021;**325**(18):1829-1830.

2. Biancolella M, Colona VL, Mehrian-Shai R, Watt JL, Luzzatto L, Novelli G, Reichardt JKV. COVID-19 2022 update: transition of the pandemic to the endemic phase. Human Genomics 2022;**16**(1):19.

3. Bayati M, Noroozi R, Ghanbari-Jahromi M, Jalali FS. Inequality in the distribution of Covid-19 vaccine: a systematic review. International Journal for Equity in Health 2022;**21**(1):122.

4. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rodés-Guirao L. A global database of COVID-19 vaccinations. Nature Human Behaviour 2021;**5**(7):947-953.

5. Razai MS, Osama T, McKechnie DGJ, Majeed A. Covid-19 vaccine hesitancy among ethnic minority groups. Bmj 2021;**372**:n513.

6. Razai MS, Kankam HKN, Majeed A, Esmail A, Williams DR. Mitigating ethnic disparities in covid-19 and beyond. Bmj 2021;**372**:m4921.

7. Bogart LM, Dong L, G, Hi P, Klein DJ, Smith TL, Ryan S, Ojikutu BO. COVID-19 Vaccine Intentions and Mistrust in a National Sample of Black Americans. Journal of the National Medical Association 2022;**113**(6):599-611.

8. Mosby I, Swidrovich J. Medical experimentation and the roots of COVID-19 vaccine hesitancy among Indigenous Peoples in Canada. Cmaj 2021;**193**(11):E381-e383.

9. Manca T, Humble RM, Aylsworth L, Cha E, Wilson SE, Meyer SB, Greyson D, Sadarangani M, Parsons Leigh J, MacDonald SE. "We need to protect each other": COVID-19 vaccination intentions and concerns

among Racialized minority and Indigenous Peoples in Canada. Soc Sci Med 2022;**313**:115400.

10. Njoku A, Joseph M, Felix R. Changing the Narrative: Structural Barriers and Racial and Ethnic Inequities in COVID-19 Vaccination. Int J Environ Res Public Health 2021;**18**(18).

11. Abba-Aji M, Stuckler D, Galea S, McKee M. Ethnic/racial minorities' and migrants' access to COVID-19 vaccines: A systematic review of barriers and facilitators. J Migr Health 2022;**5**:100086.

12. Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: realist syntheses. BMC Medicine 2013;**11**(1):21.

13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj 2021;**372**:n71.

14. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, Webster S, Cameron-Blake E, Hallas L, Majumdar S, Tatlow H. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav 2021;**5**(4):529-538.

15. Data TWB.

16. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;**65**(9):934-9.

17. Diana B-G, Georgia S, Nicola L. Studies of prevalence: how a basic epidemiology concept has gained recognition in the COVID-19 pandemic. BMJ Open 2022;**12**(10):e061497.

18. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. Bmj 2011;**342**:d549.

19. Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, Falavigna M. Meta-analysis of prevalence: I(2) statistic and how to deal with heterogeneity. Res Synth Methods 2022;**13**(3):363-367.

20. Di Giuseppe G, Pelullo CP, Lanzano R, Napolitano F, Pavia M. Knowledge, attitudes, and behavior of incarcerated people regarding COVID-19 and related vaccination: a survey in Italy. Scientific reports 2022;**12**(1):960.

21. Ousseine YM, Vaux S, V, Entorren S, Bonmarin I, Champenois K, Lydie N, Velter A. Predictors of Uncertainty and Unwillingness to Receive the COVID-19 Vaccine in Men Who Have Sex with Men in France. International journal of environmental research and public health 2022;**19**(9).

22. Attwell K, Lake J, Sneddon J, Gerrans P, Blyth C, Lee J. Converting the maybes: Crucial for a successful COVID-19 vaccination strategy. PloS One 2021;**16**(1):e0245907.

23. Seale H, Heywood AE, Leask J, Sheel M, Durrheim DN, Bolsewicz K, Kaur R. Examining Australian public perceptions and behaviors towards a future COVID-19 vaccine. BMC infectious diseases 2021;**21**(1):120.

24. Enticott J, Gill JS, Bacon SL, Lavoie KL, Epstein DS, Dawadi S, Teede HJ, Boyle J, I CST. Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis-implications for

public health communications in Australia. BMJ open 2022;**12**(1):e057127.

25. Schernhammer E, Weitzer J, Laubichler MD, Birmann BM, Bertau M, Zenk L, Caniglia G, Jäger CC, Steiner G. Correlates of COVID-19 vaccine hesitancy in Austria: trust and the government. Journal of Public Health (Oxford, England) 2022;**44**(1):e106-e116.

26. Basta NE, Sohel N, Sulis G, Wolfson C, Maimon G, Griffith LE, Kirkl, Susan, McMillan JM, Thompson M, Raina P, for the Canadian Longitudinal Study on Aging Research T. Factors Associated With Willingness to Receive a COVID-19 Vaccine Among 23,819 Adults Aged 50 Years or Older: An Analysis of the Canadian Longitudinal Study on Aging. American journal of epidemiology 2022;**191**(6):987-998.

27. Lavoie K, Gosselin-Boucher V, Stojanovic J, Gupta S, Gagne M, Joyal-Desmarais K, Seguin K, Gorin SS, Ribeiro P, Voisard B, Vallis M, Corace K, Presseau J, Bacon S, I CST. Understanding national trends in COVID-19 vaccine hesitancy in Canada: results from five sequential cross-sectional representative surveys spanning April 2020-March 2021. BMJ open 2022;**12**(4):e059411.

28. Bagic D, Suljok A, Ancic B. Determinants and reasons for coronavirus disease 2019 vaccine hesitancy in Croatia. Croatian medical journal 2022;**63**(1):89-97.

29. Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. The European journal of health economics: HEPAC: health economics in prevention and care 2020;**21**(7):977-982.

30. Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, Gagneux-Brunon A. Intention to participate in a COVID-19 vaccine clinical trial and

to get vaccinated against COVID-19 in France during the pandemic. Vaccine 2020;**38**(45):7002-7006.

31. Montagni I, Ouazzani-Touhami K, Pouymayou A, Pereira E, Texier N, Schuck S, Tzourio C, Group C. Who is hesitant about Covid-19 vaccines? The profiling of participants in a French online cohort. Revue d'epidemiologie et de sante publique 2022;**70**(3):123-131.

32. Ward JK, Alleaume C, Peretti-Watel P, Group C. The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue. Social Science & Medicine (1982) 2020;**265**:113414.

33. Coulaud P-J, Ablona A, Bolduc N, Fast D, Bertr, Karine, Ward JK, Greyson D, Jauffret-Roustide M, Knight R. COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France. Vaccine 2022;**40**(16):2442-2456.

34. Heyerdahl LW, Vray M, Lana B, Tvardik N, Gobat N, Wanat M, Tonkin-Crine S, Anthierens S, Goossens H, Giles-Vernick T. Conditionality of COVID-19 vaccine acceptance in European countries. Vaccine 2022;**40**(9):1191-1197.

35. Bendau A, Plag J, Petzold MB, Ströhle A. COVID-19 vaccine hesitancy and related fears and anxiety. International Immunopharmacology 2021;**97**:107724.

36. Kourlaba G, Kourkouni E, Maistreli S, Tsopela C-G, Molocha N-M, Triantafyllou C, Koniordou M, Kopsidas I, Chorianopoulou E, Maroudi-Manta S, Filippou D, Zaoutis TE. Willingness of Greek general population to get a COVID-19 vaccine. Global Health Research and Policy 2021;**6**(1):3.

37. Murphy J, Vallières F, Bentall RP, Shevlin M, McBride O, Hartman TK, McKay R, Bennett K, Mason L, Gibson-Miller J, Levita L, Martinez AP, Stocks TVA, Karatzias T, Hyland P. Psychological characteristics

associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nature Communications 2021;**12**(1):29.

38. Maor Y, Caspi S. Attitudes towards influenza, and COVID-19 vaccines during the COVID-19 pandemic among a representative sample of the Jewish Israeli population. PloS one 2022;**17**(2):e0255495.

39. Caserotti M, Girardi P, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents. Social Science & Medicine (1982) 2021;**272**:113688.

40. La Vecchia C, Negri E, Alicandro G, Scarpino V. Attitudes towards influenza vaccine and a potential COVID-19 vaccine in Italy and differences across occupational groups, September 2020. La Medicina Del Lavoro 2020;**111**(6):445-448.

41. Moscardino U, Musso P, Inguglia C, Ceccon C, Miconi D, Rousseau C. Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy. Vaccine 2022;**40**(16):2379-2387.

42. Palamenghi L, Barello S, Boccia S, Graffigna G. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. European Journal of Epidemiology 2020;**35**(8):785-788.

43. Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, Tsuji M, Matsuda S, Fujino Y. Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Human Vaccines & Immunotherapeutics 2021;**17**(11):3975-3981.

44. Machida M, Nakamura I, Kojima T, Saito R, Nakaya T, Hanibuchi T, Takamiya T, Odagiri Y, Fukushima N, Kikuchi H, Amagasa S, Watanabe

H, Inoue S. Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic. Vaccines 2021;**9**(3):210.

45. Kadoya Y, Watanapongvanich S, Yuktadatta P, Putthinun P, Lartey ST, Khan MSR. Willing or Hesitant? A Socioeconomic Study on the Potential Acceptance of COVID-19 Vaccine in Japan. International Journal of Environmental Research and Public Health 2021;**18**(9):4864.

46. Sekizawa Y, Hashimoto S, Denda K, Ochi S, So M. Association between COVID-19 vaccine hesitancy and generalized trust, depression, generalized anxiety, and fear of COVID-19. BMC public health 2022;**22**(1):126.

47. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan. Vaccines 2021;**9**(1):48.

48. Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, Dias S, Leite A, Nunes C. Factors Associated with COVID-19 Vaccine Hesitancy. Vaccines 2021;**9**(3):300.

49. Khaled SM, Petcu C, Bader L, Amro I, Al-Hamadi AMHA, Al Assi M, Ali AAM, Le Trung K, Diop A, Bellaj T, Al-Thani MH, Woodruff PW, Alabdulla M, Haddad PM. Prevalence and Potential Determinants of COVID-19 Vaccine Hesitancy and Resistance in Qatar: Results from a Nationally Representative Survey of Qatari Nationals and Migrants between December 2020 and January 2021. Vaccines 2021;**9**(5):471.

50. Batty GD, Deary IJ, Altschul D. Pre-pandemic mental and physical health as predictors of COVID-19 vaccine hesitancy: evidence from a UK-wide cohort study. Annals of medicine 2022;**54**(1):274-282.

51. Freeman D, Loe BS, Chadwick A, Vaccari C, Waite F, Rosebrock L, Jenner L, Petit A, Lewandowsky S, Vanderslott S, Innocenti S, Larkin M, Giubilini A, Yu L-M, McShane H, Pollard AJ, Lambe S. COVID-19 vaccine

hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychological Medicine 2020:1-15.

52. Freeman D, Waite F, Rosebrock L, Petit A, Causier C, East A, Jenner L, Teale A-L, Carr L, Mulhall S, Bold E, Lambe S. Coronavirus conspiracy beliefs, mistrust, and compliance with government guidelines in England. Psychological Medicine 2022;**52**(2):251-263.

53. Sethi S, Kumar A, Mandal A, Shaikh M, Hall CA, Kirk JMW, Moss P, Brookes MJ, Basu S. The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy. BMJ Open 2021;**11**(6):e048856.

54. Chaudhuri K, Chakrabarti A, Ch, An JS, B, Yopadhyay S. COVID-19 vaccine hesitancy in the UK: a longitudinal household cross-sectional study. BMC public health 2022;**22**(1):104.

55. Sherman SM, Sim J, Cutts M, Dasch H, Amlot R, Rubin GJ, Sevdalis N, Smith LE. COVID-19 vaccination acceptability in the UK at the start of the vaccination programme: a nationally representative cross-sectional survey (CoVAccS - wave 2). Public health 2022;**202**:1-9.

56. Sherman SM, Smith LE, Sim J, Amlôt R, Cutts M, Dasch H, Rubin GJ, Sevdalis N. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Human Vaccines & Immunotherapeutics 2021;**17**(6):1612-1621.

57. Earnshaw VA, Eaton LA, Kalichman SC, Brousseau NM, Hill EC, Fox AB. COVID-19 conspiracy beliefs, health behaviors, and policy support. Translational Behavioral Medicine 2020;**10**(4):850-856.

58. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Annals of Internal Medicine 2020;**173**(12):964-973.

59. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine 2020;**26**:100495.

60. Reiter P, Pennell M, Katz M. Acceptability of a COVID-19 Vaccine among Adults in the United States: How Many People Would Get Vaccinated? Vaccine 2020;**38**.

61. Pogue K, Jensen JL, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, Burgess R, Berges BK, Quaye A, Poole BD. Influences on Attitudes Regarding Potential COVID-19 Vaccination in the United States. Vaccines 2020;**8**(4):E582.

62. Craig BM. United States COVID-19 Vaccination Preferences (CVP): 2020 Hindsight. The Patient 2021;**14**(3):309-318.

63. Thunström L, Ashworth M, Finnoff D, Newbold SC. Hesitancy Toward a COVID-19 Vaccine. EcoHealth 2021;**18**(1):44-60.

64. Rane MS, Kochhar S, Poehlein E, You W, Robertson MM, Zimba R, Westmorel, A. D, Romo ML, Kulkarni SG, Chang M, Berry A, A, Parcesepe AM, Maroko AR, Grov C, Nash D, Team CCCS. Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study. American journal of epidemiology 2022;**191**(4):570-583.

65. Kelly BJ, Southwell BG, McCormack LA, Bann CM, MacDonald PDM, Frasier AM, Bevc CA, Brewer NT, Squiers LB. Predictors of willingness to get a COVID-19 vaccine in the U.S. BMC Infectious Diseases 2021;**21**(1):338.

66. Iacoella C, Ralli M, Maggiolini A, Arcangeli A, Ercoli L. Acceptance of COVID-19 vaccine among persons experiencing homelessness in the City of Rome, Italy. Eur Rev Med Pharmacol Sci 2021;**25**(7):3132-3135.

67. Tucker JS, D'Amico EJ, Pedersen ER, Garvey R, Rodriguez A, Klein DJ. COVID-19 Vaccination Rates and Attitudes Among Young Adults With Recent Experiences of Homelessness. The Journal of adolescent health : official publication of the Society for Adolescent Medicine 2022;**70**(3):504-506.

68. Meehan AA, Yeh M, Gardner A, DeFoe TL, Garcia A, V, er Kelen P, Montgomery MP, Tippins AE, Carmichael AE, Gibbs Chw R, Caidi H, Mosites E, Rehman N. COVID-19 Vaccine Acceptability Among Clients and Staff of Homeless Shelters in Detroit, Michigan, February 2021. Health promotion practice 2022;**23**(1):35-41.

69. Rogers JH, Cox SN, Hughes JP, Link AC, Chow EJ, Fosse I, Lukoff M, Shim MM, Uyeki TM, Ogokeh C, Jackson ML, Boeckh M, Englund JA, Mosites E, Rolfes MA, Chu HY. Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington. Vaccine 2022;**40**(1):122-132.

70. Dietze PM, Hall C, Price O, Stewart AC, Crawford S, Peacock A, Maher L. COVID-19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout. Drug and alcohol review 2022;**41**(2):484-487.

71. Sullivan MC, Mistler C, Copenhaver MM, Wickersham JA, Ni Z, Kim RS, Shrestha R. Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder. Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2022;**41**(2):115-120.

72. Abramovich A, Pang N, Kunasekaran S, Moss A, A, Kiran T, Pinto AD. Examining COVID-19 vaccine uptake and attitudes among

2SLGBTQ+ youth experiencing homelessness. BMC public health 2022;**22**(1):122.

73. Christodoulou J, Fehrenbacher AE, Shaw EH, Vincent EM, Saleska JL. COVID-19 prevention behaviors, trust, and intent to vaccinate among youth at risk for HIV. PloS one 2022;**17**(3):e0266321.

74. Stern MF, Piasecki AM, Strick LB, Rajeshwar P, Tyagi E, Dolovich S, Patel PR, Fukunaga R, Furukawa NW. Willingness to Receive a COVID-19 Vaccination Among Incarcerated or Detained Persons in Correctional and Detention Facilities - Four States, September-December 2020. MMWR Morb Mortal Wkly Rep 2021;**70**(13):473-477.

75. Shaw J, Anderson KB, Fabi RE, Thompson CA, Harris M, Aljabbarin N, Bolourchi D, Mozo N, Lichtenstein D, Lupone CD, Larsen DA, Shaw AV. COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population. Vaccine 2022;**40**(9):1231-1237.

76. Page KR, Genovese E, Franchi M, Cella S, Fiorini G, Tlili R, Salazar S, Duvoisin A, Cailhol J, Jackson Y. COVID-19 vaccine hesitancy among undocumented migrants during the early phase of the vaccination campaign: a multicentric cross-sectional study. BMJ open 2022;**12**(3):e056591.

77. Crozier J, Christensen N, Li P, Stanley G, Clark DS, Selleck C. Rural, Underserved, and Minority Populations' Perceptions of COVID-19 Information, Testing, and Vaccination: Report from a Southern State. Population health management 2022;**25**(3):413-422.

78. Scott VP, Hiller-Venegas S, Edra K, Prickitt J, Esquivel Y, Melendrez B, Rhee KE. Factors associated with COVID-19 vaccine intent among Latino SNAP participants in Southern California. BMC public health 2022;**22**(1):653.

79. Martin CA, Marshall C, Patel P, Goss C, Jenkins DR, Ellwood C, Barton L, Price A, Brunskill NJ, Khunti K, Pareek M. SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study. PLoS Med 2021;**18**(11):e1003823.

80. Curtis HJ, Inglesby P, Morton CE, MacKenna B, Green A, Hulme W, Walker AJ, Morley J, Mehrkar A, Bacon S, Hickman G, Bates C, Croker R, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Williamson EJ, Rowan A, Fisher L, McDonald HI, Tomlinson L, Mathur R, Drysdale H, Eggo RM, Wing K, Wong AY, Forbes H, Parry J, Hester F, Harper S, O'Hanlon S, Eavis A, Jarvis R, Avramov D, Griffiths P, Fowles A, Parkes N, Douglas IJ, Evans SJ, Smeeth L, Goldacre B. Trends and clinical characteristics of COVID-19 vaccine recipients: a federated analysis of 57.9 million patients' primary care records in situ using OpenSAFELY. Br J Gen Pract 2022;**72**(714):e51-e62.

81. Cahill SR. Still in the Dark Regarding the Public Health Impact of COVID-19 on Sexual and Gender Minorities. American Journal of Public Health 2021;**111**(9):1606-1609.

82. Hussain B, Latif A, Timmons S, Nkhoma K, Nellums LB. Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies. Vaccine 2022;**40**(25):3413-3432.

83. Peters MDJ. Addressing vaccine hesitancy and resistance for COVID-19 vaccines. Int J Nurs Stud 2022;**131**:104241.

84. Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Medical Research Methodology 2022;**22**(1):287.

Table 1. General characteristics of included studies.

Author	Country	Study design	Date of data collection	Population	Sample size	Female sex proportion	Mean age	Vaccine acceptance	Hesitancy	Refusal	Unwillingness
Attwell[22]	Australia	Cross-sectional survey	29-May-20	General population	1316	60	58	65%	27%	8%	35%
Seale	Australia	Cross-sectional survey	24-Mar-20	General population	1420	52		80%	14%	6%	20%
Dietze	Australia	Cross-sectional survey	22-Dec-20	People who inject drugs at least monthly in the past 6 months	100	41	39	48%	37%	15%	52%
Enticott	Australia	Cross-sectional survey	7-Mar-21	General population	1166	49	51.7	78%	15%	7%	22%
Schernhammer	Austria	Cross-sectional survey	3-Dec-20	General population	1007	44	42	36%	23%	41%	64%
Kessels	Belgium	Cross-sectional survey	16-Oct-20	General population	2060			34%	57%	9%	66%
Lavoie	Canada	Cross-sectional survey	29-Mar-21	General population	15019	50	48	58%	0%	0%	42%
Basta	Canada	Cross-sectional survey	29-Dec-20	General population	23819	53		84%	12%	4%	16%
Abramovich	Canada	Cross-sectional survey	30-Jan-21	2SLGBTQ+ youth experiencing homelessness	139	61	20	64%	0%	0%	36%

Manca	Canada	Cross-sectional survey	10-Dec-20	Indigenous population	342	53		64%	17%	18%	35%
Bagic	Croatia	Cross-sectional survey	11-Apr-21	General population	765	52.4	49	64%	19%	17%	35%
Neumann-Böhme	Denmark	Cross-sectional survey	15-Apr-20	General population	7664			80%	12%	8%	20%
Detoc	France	Cross-sectional survey	20-Apr-20	General population	3656	89	67	78%	48%	0%	48%
Ward	France	Cross-sectional survey	4-May-20	General population	5018			76%	16%	8%	24%
Montagni	France	Cross-sectional survey	10-May-20	General population	1640	78.4		71%	11%	19%	30%
Ousseine	France	Cross-sectional survey	11-Apr-21	Men who have sex with men	18474	0	34	61%	22%	18%	40%
Coulaud	France	Cross-sectional survey	23-Dec-20	General population	3204	38.		60%	30%	10%	40%
Heyerdahl	France	Cross-sectional survey	16-Dec-20	General population	10000			57%	19%	24%	43%
Bendau	Germany	Cross-sectional survey	11-Jan-21	General population	1779	77.6	41	65%	24%	11%	35%

Kourlaba	Greece	Cross-sectional survey	3-May-20	General population	1004	51	41	58%	16%	26%	42%
Murphy	Ireland	Cross-sectional survey	5-Apr-20	General population	1041	51.5		65%	26%	9%	35%
Maor	Israel	Cross-sectional survey	6-Sep-20	General population	2024	52		76%	0%	24%	24%
Caserotti	Italy	Survey with repeated measures	30-Jun-20	General population	839	70.2	38	79%	0%	21%	21%
La Vecchia	Italy	Cross-sectional survey	28-Sep-20	General population	1055	51.7		54%	0%	46%	46%
Di Giuseppe	Italy	Cross-sectional survey	28-Apr-21	Incarcerated	685	0	42.4	64%	0%	36%	36%
Moscardino	Italy	Cross-sectional survey	28-Jun-21	General population	1200	49.2	29.8	73%	18%	8%	25%
Palamenghi	Italy	Cross-sectional survey		General population	968			59%	0%	41%	41%
Iacoella	Italy	Cross-sectional survey	15-Feb-21	persons experiencing homelessness	112	24.1	53.1	63%	4%	32%	36%
Yoda	Japan	Cross-sectional survey	30-Sep-20	General population	1100	46.9	44.8	66%	22%	12%	34%
Ihshimaru	Japan	Cross-sectional survey	26-Dec-20	General population	27036	48.9		38%	0%	63%	63%

Machida	Japan	Cross-sectional survey	18-Jan-21	General population	2956	50.6		62%	0%	38%	38%
Kadoya	Japan	Cross-sectional survey	25-Feb-21	General population	4253	35	50.3	47%	31%	22%	53%
Sekizawa	Japan	Cross-sectional survey	6-May-21	General population	11846	49.6	54	62%	30%	9%	38%
Soares	Portugal	Cross-sectional survey	8-Jan-21	General population	1943	67.7	47.7	35%	56%	9%	65%
Khaled	Qatar	Cross-sectional survey	25-Jan-21	General population	1912	31.7		43%	45%	12%	57%
Page	Switzerland	Cross-sectional survey	31-May-21	Undocumented migrants	812	60.9	39	41%	0%	59%	59%
Freeman	UK	Cross-sectional survey	11-May-20	General population	2501	51.4	46.6	48%	7%	5%	12%
Sethi	UK	Cross-sectional survey	9-Oct-20	General population	4884	69.9		79%	14%	7%	21%
Freeman	UK	Cross-sectional survey	17-Oct-20	General population	5114	49.2	46.9	72%	17%	12%	28%
Batty	UK	Cross-sectional survey	31-Dec-20	General population	11955	56.4		85%	15%	0%	15%

Chaudhuri	UK	Cross-sectional survey	31-Jan-21	General population	22421	58.5	55.4	89%	0%	11%	11%
Sherman	UK	Cross-sectional survey	17-Jul-20	General population	1494	51	46	64%	27%	9%	36%
Sherman	UK	Cross-sectional survey	15-Jan-21	General population	1500	51	45.6	74%	14%	9%	23%
Earnshaw	USA	Cross-sectional survey	14-Apr-20	General population	845	40.9	40	86%	0%	0%	14%
Fisher	USA	Cross-sectional survey	20-Apr-20	General population	991	51.5	18	58%	32%	11%	42%
Malik	USA	Cross-sectional survey	1-May-20	General population	672	57		67%	0%	0%	33%
Reiter	USA	Cross-sectional survey	31-May-20	General population	2006	56		48%	43%	9%	52%
Pogue	USA	Cross-sectional survey		General population	316	49.4		68%	23%	9%	32%
Craig	USA	Discrete choice experiment survey	11-Nov-20	General population	1153	52.3		61%	0%	17%	17%
Kelly	USA	Cross-sectional survey	30-Apr-20	General population	2279	52		75%	0%	25%	25%

Christodoulou	USA	Cross-sectional survey	30-Apr-20	Youth aged 18–28 at-risk for HIV	83	16	23	65%	0%	35%	35%
Sullivan	USA	Cross-sectional survey	01-May-20	People with opioid use disorder	234	56	46.8	32%	48%	20%	68%
Stern	USA	Cross-sectional survey	12-Dec-20	Incarcerated or detained persons	5110	17.6		45%	10%	45%	55%
Rogers	USA	Cross-sectional survey	28-Feb-21	Adult homeless shelter residents and staff	969	27.4	41	54%	18%	28%	46%
Crozier	USA	Cross-sectional survey	31-Dec-20	Rural, Underserved and Minority Populations in Alabama	3721	56.5		39%	27%	24%	51%
Thunström	USA	Cross-sectional survey	31-Mar-20	General population	3133	52	46	80%	0%	20%	20%
Rane	USA	Survey with repeated measures	01-Oct-20	General population	4571	53		85%	9%	6%	15%
Scott	USA	Cross-sectional survey	31-Jul-20	Latino SNAP participants (food programme)	486	93	40	48%	39%	13%	52%
Bogart	USA	Cross-sectional survey	31-Dec-20	Black Americans	207	71	50.8	30%	38%	32%	70%
Rosen	USA	Cross-sectional survey	31-May-21	Unhoused People in Los Angeles County	4949			74%	7%	17%	25%

Tucker	USA	Cross-sectional survey	1-Mar-21	Young adults with recent experiences of homelessness	134	32		50%	0%	50%	50%
Shaw	USA	Cross-sectional survey	1-Mar-21	Refugees	244	55.3	38.5	57%	18%	25%	43%
Nguyen	USA	Cross-sectional survey	2-Aug-20	General population	63266	50.6		86%	5%	9%	14%
Meehan	USA	Cross-sectional survey	23-Feb-21	Clients and staff of homeless shelters	106		44	58%	11%	31%	42%

Figures

Figure 1. Random-effects meta-analysis of COVID-19 vaccine acceptance in the general population



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval

Figure 2. Random-effects meta-analysis of COVID-19 vaccine acceptance in special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Table of contents for the supplementary material

Supplementary material

1. **Supplementary section 1: methods**

a. **Search**

Search date: November 30 2022 (last date searched)

(exp Coronaviridae/exp Coronavirus Infections/(2019 novel coronavirus disease or COVID19 or sarscov 2 infection or SARS coronavir* or 2019 novel coronavirus infection or 2019 ncov infection or 2019 ncov disease).ti,ab.) AND (exp Vaccines/exp Immunization/or ((vaccin* or immun* or Influenza Vaccines or COVID-19 Vaccin*) adj3 COVID-19).ti,ab.) AND (exp "Patient Acceptance of Health Care"/exp Vaccination/exp Attitude/or (Willingness or readiness or preparedness or disposition or acceptance or acceptability or perception or receptivity or hesitancy or intention or attitudes).ti,ab. not exp animals/)

b. Figure S1 Flow diagram for selection of studies



c. List of excluded references after full-text screening

Exclusion reason	Reference
Wrong population (n=103)	1-103
Convenience sample (n=23)	104-126
Outcomes missing (n=21)	127-147
Qualitative study (n=3)	148-150
Focusing on booster vaccine (n=2)	151-152

1. Galanis, P. *et al.* Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: A systematic review and meta-analysis. *Preventive medicine* 157, 106994 (2022)
2. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States - ScienceDirect. (2022).
3. Luo, H. *et al.* Willingness to Get a COVID-19 Vaccine and Reasons for Hesitancy Among Medicare Beneficiaries: Results From a National Survey. *Journal of public health management and practice : JPHMP* 28, 70–76 (2022).
4. Serrazina, F., Sobral Pinho, A., Cabral, G., Salavisa, M. & Correia, A. S. Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients. *Mult Scler Relat Disord* 51, 102880 (2021).
5. Unroe, K., Evans, R., Weaver, L., Rusyniak, D. & Blackburn, J. Willingness of Long-Term Care Staff to Receive a COVID -19 Vaccine: A Single State Survey. *Journal of the American Geriatrics Society* 69, (2020).
6. Wagner, E. F. *et al.* Virtual town halls addressing vaccine hesitancy among racial/ethnic minorities: Preliminary findings. *Journal of the American Pharmacists Association : JAPhA* 62, 317–325 (2022).
7. Vaccines | Free Full-Text | Intention to Be Vaccinated for COVID-19 among Italian Nurses during the Pandemic. (2022).
8. Vaccines | Free Full-Text | Attitudes towards COVID-19 Vaccination among Hospital Staff—Understanding What Matters to Hesitant People. (2022).
9. 'Vaccine hesitancy' among university students in Italy during the COVID-19 pandemic | SpringerLink. (2022).
10. Lo Moro, G., Cugudda, E., Bert, F., Raco, I. & Siliquini, R. Vaccine Hesitancy and Fear of COVID-19 Among Italian Medical Students: A Cross-Sectional Study. *Journal of community health* 47, 475–483 (2022).
11. Kelkar, A. H. *et al.* Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar. *Healthcare (Basel)* 9, 351 (2021).
12. Riad, A. *et al.* Universal Predictors of Dental Students' Attitudes towards COVID-19 Vaccination: Machine Learning-Based Approach. *Vaccines (Basel)* 9, 1158 (2021).
13. Lennon, R. P. *et al.* Unique Predictors of Intended Uptake of a COVID-19 Vaccine in Adults Living in a Rural College Town in the United States. *American journal of health promotion : AJHP* 36, 180–184 (2022).
14. Euser, S., Kroese, F. M., Derks, M. & de Bruin, M. Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands. *Vaccine* 40, 833–836 (2022).
15. Trent, M., Seale, H., Chughtai, A. A., Salmon, D. & MacIntyre, C. R. Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the United States, United Kingdom, and Australia. *Vaccine* 40, 2498–2505 (2022).

16. Hosokawa, Y. *et al.* The Prevalence of COVID-19 Vaccination and Vaccine Hesitancy in Pregnant Women: An Internet-based Cross-sectional Study in Japan. *Journal of epidemiology* 32, 188–194 (2022).
17. Grüner, S. & Krüger, F. The intention to be vaccinated against COVID-19: stated preferences before vaccines were available. *Applied Economics Letters* 28, 1847–1851 (2021).
18. Kavanagh, A., Dickinson, H., Dimov, S., Shields, M. & McAllister, A. The COVID-19 vaccine intentions of Australian disability support workers. *Australian and New Zealand journal of public health* 46, 314–321 (2022).
19. Harsch, I. A., Ortloff, A., Reinhöfer, M. & Epstude, J. Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers. *GMS Hyg Infect Control* 16, Doc15 (2021).
20. G, D. G. *et al.* Surveying willingness toward SARS-CoV-2 vaccination of healthcare workers in Italy. *Expert review of vaccines* 20, (2021).
21. Chapman, G. *et al.* 'Scary to get, more scary not to': COVID-19 vaccine acceptance among healthcare workers in Central Queensland, Australia, a cross-sectional survey. *Communicable diseases intelligence (2018)* 46, (2022).
22. Stuckelberger, S. *et al.* SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland. *Viruses* 13, 1199 (2021).
23. Jaiswal, J. *et al.* SARS-CoV-2 Vaccination Hesitancy and Behaviors in a National Sample of People Living with HIV. *AIDS patient care and STDs* 36, 34–44 (2022).
24. Temsah, M.-H. *et al.* SARS-CoV-2 B.1.1.7 UK Variant of Concern Lineage-Related Perceptions, COVID-19 Vaccine Acceptance and Travel Worry Among Healthcare Workers. *Front Public Health* 9, 686958 (2021).
25. Grafova, I. B. *et al.* Racial and ethnic differences in vaccine hesitancy Among registered nurses in New Jersey: A cross-sectional survey. *American journal of infection control* 50, 572–574 (2022).
26. Niznik, J. D. *et al.* Perceptions of COVID-19 vaccines among healthcare assistants: A national survey. *Journal of the American Geriatrics Society* 70, 8–18 (2022).
27. Hogan, C. M. *et al.* Perceptions of COVID-19 Vaccine Incentives Among Adolescents and Young Adults. *JAMA network open* 5, e2216628 (2022).
28. Alhazza, S. F. *et al.* Parents' Hesitancy to Vaccinate Their Children Against COVID-19, a Country-Wide Survey. *Frontiers in public health* 10, 755073 (2022).
29. Bell, S., Clarke, R., Mounier-Jack, S., Walker, J. L. & Paterson, P. Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. *Vaccine* 38, 7789–7798 (2020).
30. Bianco, A. *et al.* Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy. *Expert review of vaccines* 21, 541–547 (2022).
31. Choi, K., Becerra-Culqui, T., Bhakta, B., Bruxvoort, K. & Coleman, K. J. Parent intentions to vaccinate children with autism spectrum disorder against COVID-19. *Journal of pediatric nursing* 63, 108–110 (2022).
32. Afifi, T. O. *et al.* Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies. *Vaccine* 3473–3479 (2021).
33. Pierantoni, L. *et al.* Nationwide COVID-19 survey of Italian parents reveals useful information on attitudes to school attendance, medical support, vaccines and drug trials. *Acta Paediatr* 10.1111/apa.15614 (2020) doi:10.1111/apa.15614.
34. Brandt, E. J. *et al.* National Study of Youth Opinions on Vaccination for COVID-19 in the U.S. *J Adolesc Health* 68, 869–872 (2021).
35. Szmyd, B. *et al.* Medical Students and SARS-CoV-2 Vaccination: Attitude and Behaviors. *Vaccines (Basel)* 9, 128 (2021).
36. Halbrook, M. *et al.* Longitudinal Assessment of Coronavirus Disease 2019 Vaccine Acceptance and Uptake Among Frontline Medical Workers in Los Angeles, California. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 74, 1166–1173 (2022).

37. Ciardi, F. *et al.* Knowledge, Attitudes and Perceptions of COVID-19 Vaccination among Healthcare Workers of an Inner-City Hospital in New York. *Vaccines (Basel)* 9, 516 (2021).
38. Elhadi, M. *et al.* Knowledge, attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine: a cross-sectional study. *BMC Public Health* 21, 955 (2021).
39. Kreuter, M. W. *et al.* Intention to vaccinate children for COVID-19: A segmentation analysis among Medicaid parents in Florida. *Preventive medicine* 156, 106959 (2022).
40. Kaida, A. *et al.* Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada. *AIDS and behavior* 26, 2242–2255 (2022).
41. Gagneux-Brunon, A. *et al.* Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey. *Journal of Hospital Infection* 108, 168–173 (2021).
42. Talarek, E., Warzecha, J., Banasiuk, M. & Banaszkiewicz, A. Influenza Vaccination Coverage and Intention to Receive Hypothetical Ebola and COVID-19 Vaccines among Medical Students. *Vaccines (Basel)* 9, 709 (2021).
43. Caron, B., Neuville, E. & Peyrin-Biroulet, L. Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey. *Digestive diseases and sciences* 67, 2067–2073 (2022).
44. Impact of the COVID-19 pandemic on ophthalmic specialist training in Poland. | PLoS One;16(9): e0257876, 2021. | MEDLINE. (2022).
45. Janssen, C. *et al.* Hesitancy towards COVID-19 Vaccination among Healthcare Workers: A Multi-Centric Survey in France. *Vaccines* 9, 547 (2021).
46. Baghdadi, L. R., Alghaihb, S. G., Abuhaimed, A. A., Alkelabi, D. M. & Alqahtani, R. S. Healthcare Workers' Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study. *Vaccines (Basel)* 9, 465 (2021).
47. Patil, U. *et al.* Health Literacy, Digital Health Literacy, and COVID-19 Pandemic Attitudes and Behaviors in U.S. College Students: Implications for Interventions. *International Journal of Environmental Research and Public Health* 18, 3301 (2021).
48. Thompson, H. S. *et al.* Factors Associated With Racial/Ethnic Group–Based Medical Mistrust and Perspectives on COVID-19 Vaccine Trial Participation and Vaccine Uptake in the US. *JAMA Netw Open* 4, e2111629 (2021).
49. Goldman, R. D. *et al.* Factors associated with parents' willingness to enroll their children in trials for COVID-19 vaccination. *Hum Vaccin Immunother* 17, 1607–1611 (2022).
50. Letterie, M. C. *et al.* Factors Associated With Parental COVID-19 Vaccination Acceptance. *Clinical pediatrics* 61, 393–401 (2022).
51. Puteikis, K. & Mameniškienė, R. Factors Associated with COVID-19 Vaccine Hesitancy among People with Epilepsy in Lithuania. *Int J Environ Res Public Health* 18, 4374 (2021).
52. Daniel, C. L., Williams, J., Legg, R., McGowen, C. & Stutzman, J. Factors associated with COVID-19 vaccination intentions among adults in the deep South. *Vaccine* 40, 841–853 (2022).
53. Skeens, M. A. *et al.* Factors affecting COVID-19 vaccine hesitancy in parents of children with cancer. *Pediatric blood & cancer* 69, e29707 (2022).
54. Di Giuseppe, G., Pelullo, C. P., Della Polla, G., Pavia, M. & Angelillo, I. F. Exploring the Willingness to Accept SARS-CoV-2 Vaccine in a University Population in Southern Italy, September to November 2020. *Vaccines (Basel)* 9, 275 (2021).
55. Purnell, M. *et al.* Exploring COVID-19 vaccine hesitancy at a rural historically black college and university. *Journal of the American Pharmacists Association : JAPhA* 62, 340–344 (2022).
56. Hahn, M. B., Fried, R. L., Cochran, P. & Eichelberger, L. P. Evolving perceptions of COVID-19 vaccines among remote Alaskan communities. *International journal of circumpolar health* 81, 2021684 (2022).
57. Gravelle, T. B., Phillips, J. B., Reifler, J. & Scotto, T. J. Estimating the size of 'anti-vax' and vaccine hesitant populations in the US, UK, and Canada: comparative latent class modeling of vaccine attitudes. *Human vaccines & immunotherapeutics* 18, 2008214 (2022).

58. Enhancing COVID-19 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy - PubMed. (2022).
59. Maltezou, H. C. *et al.* Determinants of intention to get vaccinated against COVID-19 among healthcare personnel in hospitals in Greece. *Infect Dis Health* 26, 189–197 (2021).
60. Gray, A. & Fisher, C. B. Determinants of COVID-19 Vaccine Uptake in Adolescents 12-17 Years Old: Examining Pediatric Vaccine Hesitancy Among Racially Diverse Parents in the United States. *Frontiers in public health* 10, 844310 (2022).
61. Costantino, A. *et al.* COVID-19 Vaccine: A Survey of Hesitancy in Patients with Celiac Disease. *Vaccines* 9, 511 (2021).
62. Jefsen, O. H. *et al.* COVID-19 vaccine willingness amongst patients with mental illness compared with the general population. *Acta Neuropsychiatrica* 33, 273–276 (2021).
63. Chudasama, R. V. *et al.* COVID-19 vaccine uptake and hesitancy opinions from frontline health care and social care workers: Survey data from 37 countries. *Diabetes & metabolic syndrome* 16, 102361 (2022).
64. Doyle-Campbell, C., Mattison, M. J., Amedeo, V., Gaffney, S. & Achadinha, H. COVID-19 vaccine status and hesitancy in pharmacy students. *Currents in pharmacy teaching & learning* 14, 476–481 (2022).
65. Iadarola, S., Siegel, J. F., Gao, Q., McGrath, K. & Bonuck, K. A. COVID-19 vaccine perceptions in New York State's intellectual and developmental disabilities community. *Disability and health journal* 15, 101178 (2022).
66. Lutrick, K. *et al.* COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers. *Vaccine* 40, 494–502 (2022).
67. Watts, A. W. *et al.* COVID-19 Vaccine Intentions and Perceptions Among Public School Staff of the Greater Vancouver Metropolitan Area, British Columbia, Canada. *Frontiers in public health* 10, 832444 (2022).
68. Gurenlian, J. R. *et al.* COVID-19 Vaccine Intention and Hesitancy of Dental Hygienists in the United States. *Journal of dental hygiene : JDH* 96, 5–16 (2022).
69. Wu, H., Ward, M., Brown, A., Blackwell, E. & Umer, A. COVID-19 Vaccine intent in appalachian patients with multiple sclerosis. *Multiple sclerosis and related disorders* 57, 103450 (2022).
70. Sieber, W. J. *et al.* COVID-19 vaccine hesitancy: Associations with gender, race, and source of health information. *Families, systems & health : the journal of collaborative family healthcare* 40, 252–261 (2022).
71. Fedele, F. *et al.* COVID-19 vaccine hesitancy: a survey in a population highly compliant to common vaccinations. *Human Vaccines & Immunotherapeutics* 17, 3348–3354 (2021).
72. Uhr, L. & Mateen, F. J. COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey. *Multiple sclerosis (Houndmills, Basingstoke, England)* 28, 1072–1080 (2022).
73. Al-Mulla, R., Abu-Madi, M., Talafha, Q. M., Tayyem, R. F. & Abdallah, A. M. COVID-19 Vaccine Hesitancy in a Representative Education Sector Population in Qatar. *Vaccines* 9, 665 (2021).
74. Yang, Y., Dobalian, A. & Ward, K. D. COVID-19 Vaccine Hesitancy and Its Determinants Among Adults with a History of Tobacco or Marijuana Use. *J Community Health* 46, 1090–1098 (2021).
75. Tsai, R. *et al.* COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey. *JMIR public health and surveillance* 8, e29872 (2022).
76. Hubach, R. *et al.* COVID-19 vaccine hesitancy among rural Oklahomans. *Rural and remote health* 22, 7128 (2022).
77. Lucia, V. C., Kelekar, A. & Afonso, N. M. COVID-19 vaccine hesitancy among medical students. *J Public Health (Oxf)* fdaa230 (2020) doi:10.1093/pubmed/fdaa230.
78. Teasdale, C. A. *et al.* COVID-19 Vaccine Coverage and Hesitancy Among New York City Parents of Children Aged 5-11 Years. *American journal of public health* 112, 931–936 (2022).

79. Morris, J. L., Baniak, L. M., Luyster, F. S. & Dunbar-Jacob, J. Covid-19 vaccine confidence and hesitancy in nursing students and faculty at a large academic medical center. *Nursing outlook* 70, 347–354 (2022).
80. Dzieciolowska, S. *et al.* Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: A multicenter survey. *Am J Infect Control* 49, 1152–1157 (2021).
81. Kelekar, A. K., Lucia, V. C., Afonso, N. M. & Mascarenhas, A. K. COVID-19 vaccine acceptance and hesitancy among dental and medical students. *The Journal of the American Dental Association* 152, 596–603 (2021).
82. Shaaban, R. *et al.* COVID-19 Vaccine Acceptance among Social Media Users: A Content Analysis, Multi-Continent Study. *International journal of environmental research and public health* 19, (2022).
83. COVID-19 Vaccine Acceptance Among Health Care Workers in the United States | medRxiv. (2022).
84. Kozak, A. & Nienhaus, A. COVID-19 Vaccination: Status and Willingness to Be Vaccinated among Employees in Health and Welfare Care in Germany. *Int J Environ Res Public Health* 18, 6688 (2021).
85. Xiang, X. M. *et al.* COVID-19 vaccination willingness among people with multiple sclerosis. *Mult Scler J Exp Transl Clin* 7, 20552173211017160 (2021).
86. Fulda, E. S. *et al.* COVID-19 Vaccination Rates in a Global HIV Cohort. *The Journal of infectious diseases* 225, 603–607 (2022).
87. Myers, A., Ipsen, C. & Lissau, A. COVID-19 vaccination hesitancy among Americans with disabilities aged 18-65: An exploratory analysis. *Disability and health journal* 15, 101223 (2022).
88. Kecojevic, A., Basch, C. H., Sullivan, M., Chen, Y.-T. & Davi, N. K. COVID-19 Vaccination and Intention to Vaccinate Among a Sample of College Students in New Jersey. *J Community Health* 46, 1059–1068 (2021).
89. Haile, Z. T., Ruhil, A., Bates, B. R., Hall, O. & Grijalva, M. J. Correlates of Covid-19 Vaccine Acceptance among Residents of Ohio: A Cross-sectional Study. *BMC public health* 22, 226 (2022).
90. Goldman, R. D. *et al.* Caregivers' Willingness to Accept Expedited Vaccine Research During the COVID-19 Pandemic: A Cross-sectional Survey. *Clin Ther* 42, 2124–2133 (2020).
91. Heyne, S., Esser, P., Werner, A., Lehmann-Laue, A. & Mehnert-Theuerkauf, A. Attitudes toward a COVID-19 vaccine and vaccination status in cancer patients: a cross-sectional survey. *Journal of cancer research and clinical oncology* 148, 1363–1374 (2022).
92. Attitudes of Patients with Cancer towards Vaccinations—Results of Online Survey with Special Focus on the Vaccination against COVID-19 - PMC. (2022).
93. Verger, P. *et al.* Attitudes of healthcare workers towards COVID-19 vaccination: a survey in France and French-speaking parts of Belgium and Canada, 2020. *Euro Surveill* 26, (2021).
94. Szmyd, B. *et al.* Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland. *Vaccines (Basel)* 9, 218 (2021).
95. Eyllon, M. *et al.* Associations between psychiatric morbidity and COVID-19 vaccine hesitancy: An analysis of electronic health records and patient survey. *Psychiatry research* 307, 114329 (2022).
96. Bellis, M. A. *et al.* Associations between adverse childhood experiences, attitudes towards COVID-19 restrictions and vaccine hesitancy: a cross-sectional study. *BMJ open* 12, e053915 (2022).
97. Shaw, J. *et al.* Assessment of US Healthcare Personnel Attitudes Towards Coronavirus Disease 2019 (COVID-19) Vaccination in a Large University Healthcare System. *Clin Infect Dis* 73, 1776–1783 (2021).
98. Gardner, J. *et al.* An assessment of Veterans attitudes and willingness to receiving the COVID-19 vaccine: a mixed methods study. *BMC infectious diseases* 22, 308 (2022).
99. Temsah, M.-H. *et al.* Adenovirus and RNA-based COVID-19 vaccines' perceptions and acceptance among healthcare workers in Saudi Arabia: a national survey. *BMJ Open* 11, e048586 (2021).

100. de Sousa, M. J. *et al.* Acceptance of SARS-CoV-2 vaccination among cancer patients in Portugal: attitudes and associated factors. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 30, 4565–4570 (2022).
101. Nohl, A. *et al.* Acceptance of COVID-19 Vaccination among Front-Line Health Care Workers: A Nationwide Survey of Emergency Medical Services Personnel from Germany. *Vaccines (Basel)* 9, 424 (2021).
102. Pataka, A. *et al.* Acceptability of healthcare professionals to get vaccinated against COVID-19 two weeks before initiation of national vaccination in Greece. *European Respiratory Journal* 58, (2021).
103. Qattan, A. M. N. *et al.* Acceptability of a COVID-19 Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia. *Front Med (Lausanne)* 8, 644300 (2021).
104. Qunaibi, E. A. *et al.* A high rate of COVID-19 vaccine hesitancy in a large-scale survey on Arabs. *eLife* 10, e68038 (2021).
105. Latkin, C. *et al.* A longitudinal study of vaccine hesitancy attitudes and social influence as predictors of COVID-19 vaccine uptake in the US. *Human vaccines & immunotherapeutics* 18, 2043102 (2022).
106. Alqudeimat, Y. *et al.* Acceptance of a COVID-19 Vaccine and Its Related Determinants among the General Adult Population in Kuwait. *Med Princ Pract* 30, 262–271 (2021).
107. Babicki, M. & Mastalerz-Migas, A. Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland. *Vaccines (Basel)* 9, 503 (2021).
108. Gasteiger, N., Gasteiger, C., Vedhara, K. & Broadbent, E. Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach. *Vaccine* 40, 3461–3465 (2022).
109. Romer, D. & Jamieson, K. H. Conspiracy theories as barriers to controlling the spread of COVID-19 in the U.S. *Soc Sci Med* 263, 113356 (2020).
110. Brownstein, N. C. *et al.* COVID-19 vaccine behaviors and intentions among a national sample of United States adults ages 18-45. *Preventive medicine* 160, 107038 (2022).
111. Niankara, I. COVID-19 Vaccine Development in a Quadruple Helix Innovation System: Uncovering the Preferences of the Fourth Helix in the UAE. *Journal of Open Innovation: Technology, Market, and Complexity* 132–132 (2020).
112. Holeva, V., Parlapani, E., Nikopoulou, V. A., Nouskas, I. & Diakogiannis, I. COVID-19 vaccine hesitancy in a sample of Greek adults. *Psychology, health & medicine* 27, 113–119 (2022).
113. Waite, N. M., Pereira, J. A., Houle, S. K. D., Gilca, V. & Andrew, M. K. COVID-19's Impact on Willingness to Be Vaccinated against Influenza and COVID-19 during the 2020/2021 Season: Results from an Online Survey of Canadian Adults 50 Years and Older. *Vaccines (Basel)* 9, 346 (2021).
114. COVID-19 vaccine hesitancy and attitudes in Qatar: A national cross-sectional survey of a migrant-majority population - Alabdulla - 2021 - Influenza and Other Respiratory Viruses - Wiley Online Library. (2022).
115. Al-Mohaithef, M. & Padhi, B. K. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. *J Multidiscip Healthc* 13, 1657–1663 (2020).
116. Kreps, S. *et al.* Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. *JAMA Netw Open* 3, e2025594 (2020).
117. Dorman, C. *et al.* Factors Associated with Willingness to be Vaccinated Against COVID-19 in a Large Convenience Sample. *J Community Health* 46, 1013–1019 (2021).
118. Nikolovski, J. *et al.* Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. *PLoS One* 16, e0251963 (2021).
119. Sallam, M. *et al.* High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. *Vaccines (Basel)* 9, 42 (2021).

120. Biasio, L. R., Bonaccorsi, G., Lorini, C., Mazzini, D. & Pecorelli, S. Italian Adults' Likelihood of Getting COVID-19 Vaccine: A Second Online Survey. *Vaccines (Basel)* 9, 268 (2021).
121. Gutierrez, S., Logan, R., Marshall, C., Kerns, J. & Diamond-Smith, N. Predictors of COVID-19 Vaccination Likelihood Among Reproductive-Aged Women in the United States. *Public health reports (Washington, D.C. : 1974)* 137, 588–596 (2022).
122. Faasse, K. & Newby, J. Public Perceptions of COVID-19 in Australia: Perceived Risk, Knowledge, Health-Protective Behaviors, and Vaccine Intentions. *Front Psychol* 11, 551004 (2020).
123. Nguyen, L. H. *et al.* Self-reported COVID-19 vaccine hesitancy and uptake among participants from different racial and ethnic groups in the United States and United Kingdom. *Nature communications* 13, 636 (2022).
124. Sethi, S. *et al.* The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy. *BMJ Open* 11, e048856 (2021).
125. Abu-Farha, R. *et al.* Willingness of Middle Eastern public to receive COVID-19 vaccines. *Saudi Pharm J* 29, 734–739 (2021).
126. Willingness to Be Vaccinated against COVID-19 in Spain before the Start of Vaccination: A Cross-Sectional Study - PubMed. (2022).
127. García, L. Y. & Cerda, A. A. Contingent assessment of the COVID-19 vaccine. *Vaccine* 38, 5424–5429 (2020).
128. Freeman, D. *et al.* Coronavirus conspiracy beliefs, mistrust, and compliance with government guidelines in England. *Psychological medicine* 52, 251–263 (2022).
129. Fridman, A., Gershon, R. & Gneezy, A. COVID-19 and vaccine hesitancy: A longitudinal study. *PLoS One* 16, e0250123 (2021).
130. Knight, K. R. *et al.* COVID-19 Testing and Vaccine Acceptability Among Homeless-Experienced Adults: Qualitative Data from Two Samples. *Journal of general internal medicine* 37, 823–829 (2022).
131. Salali, G. D. & Uysal, M. S. COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. *Psychol Med* 1–3 (2022) doi:10.1017/S0033291720004067.
132. Levin, J. & Bradshaw, M. Determinants of COVID-19 skepticism and SARS-CoV-2 vaccine hesitancy: findings from a national population survey of U.S. adults. *BMC public health* 22, 1047 (2022).
133. Frontiers | A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2 | Psychology. (2022).
134. McCaffery, K. J. *et al.* Health literacy and disparities in COVID-19-related knowledge, attitudes, beliefs and behaviours in Australia. *Public Health Res Pract* 30, 30342012 (2020).
135. Borriello, A., Master, D., Pellegrini, A. & Rose, J. M. Preferences for a COVID-19 vaccine in Australia. *Vaccine* 39, 473–479 (2021).
136. Kreps, S., Dasgupta, N., Brownstein, J. S., Hswen, Y. & Kriner, D. L. Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation. *NPJ Vaccines* 6, 73 (2021).
137. Hursh, S. R., Strickland, J. C., Schwartz, L. P. & Reed, D. D. Quantifying the Impact of Public Perceptions on Vaccine Acceptance Using Behavioral Economics. *Front Public Health* 8, 608852 (2020).
138. Benis, A., Seidmann, A. & Ashkenazi, S. Reasons for Taking the COVID-19 Vaccine by US Social Media Users. *Vaccines (Basel)* 9, 315 (2021).
139. Callaghan, T., Lueck, J. A., Trujillo, K. L. & Ferdinand, A. O. Rural and Urban Differences in COVID-19 Prevention Behaviors. *The Journal of Rural Health* 37, 287–295 (2021).
140. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine. *Ugeskriftet.dk* (2022).

141. Ku, L. The Association of Social Factors and Health Insurance Coverage with COVID-19 Vaccinations and Hesitancy, July 2021. *Journal of general internal medicine* 37, 409–414 (2022).

Items	Description
Study Identification	Authors, journal, and date of publication, doi
Study design	Quantitative, Qualitative, Other
Data Collection	Period of data collection
Geographic Context	Country, City/State, multi-country study
Sampling Method	Survey, Interviews, Other
Study size	Number of participants
Study population	General Population or marginalized, mean age, gender ratio, other characteristics if reported
Vaccine acceptability	Percentage of population accepting, being hesitant about, or refusing a Covid-19 vaccine
Promoters	Reasons for accepting a vaccine
Barriers	Reasons for refusing a vaccine
Demographic characteristics	Vaccine acceptance, hesitancy and refusal across demographic characteristics, as

142. Rzymski, P., Zeyland, J., Poniedziałek, B., Małecka, I. & Wysocki, J. The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland. *Vaccines (Basel)* 9, 382 (2021).
143. Felemban, R. M., Tashkandi, E. M. & Mohorjy, D. K. The willingness of the Saudi Arabian population to participate in the COVID-19 vaccine trial: A case-control study. *J Taibah Univ Med Sci* 16, 612–618 (2021).
144. Guidry, J. P. D. *et al.* U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic. *Vaccine* 39, 2452–2457 (2021).
145. Dror, A. A. *et al.* Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol* 35, 775–779 (2020).
146. Catma, S. & Varol, S. Willingness to Pay for a Hypothetical COVID-19 Vaccine in the United States: A Contingent Valuation Approach. *Vaccine* (2021) doi:10.3390/vaccines9040318.
147. Burch, A. E., Lee, E., Shackelford, P., Schmidt, P. & Bolin, P. Willingness to Vaccinate Against COVID-19: Predictors of Vaccine Uptake Among Adults in the US. *Journal of prevention (2022)* 43, 83–93 (2022).
148. McFadden, S. M. *et al.* Confidence and Hesitancy During the Early Roll-out of COVID-19 Vaccines Among Black, Hispanic, and Undocumented Immigrant Communities: a Review. *Journal of urban health : bulletin of the New York Academy of Medicine* 99, 3–14 (2022).
149. Butler, J. Z. *et al.* COVID-19 vaccination readiness among multiple racial and ethnic groups in the San Francisco Bay Area: A qualitative analysis. *PloS one* 17, e0266397 (2022).
150. Teixeira da Silva, D. *et al.* COVID-19 Vaccine Acceptance among an Online Sample of Sexual and Gender Minority Men and Transgender Women. *Vaccines (Basel)* 9, 204 (2021).
151. Sonderskov, K. M., Vistisen, H. T., Dinesen, P. T. & Ostergaard, S. D. A positive update on COVID-19 booster vaccine willingness among Danes. *Danish medical journal* 69, (2022).
152. Lennon, R. P. *et al.* Underserved population acceptance of combination influenza-COVID-19 booster vaccines. *Vaccine* 40, 562–567 (2022).

	reported

d. Definitions of variables and sources

For individual studies:

Per country :

Data Sources : OECD, The World Bank, National Public Health Offices, Ourworldindata.org, US National Center for Education Statistics, Eurostat Database, Pew Research Center

Currency is current US dollars

Items	Description
Vaccination Data	
Vaccine approval	Date of first vaccine approval
Vaccination rates, past	Double, single and total vaccination rates as of 26.11.2021
General Demographic Data	
Population	Total population and percentage of foreign-born population
Gender ratio	Percentage of male population
Population, old	Population ages 65 and above, total
Life expectancy	Life expectancy at birth, total years
Religion and Ethnicity	
Religion and Ethnicity	Undenominational, Christians, Muslims, Hindus, Jews, Folk Religions, Buddhists, Others. Pew Research Center
Education	
Educational attainment	Educational attainment, primary to Doctoral or equivalent, population 25+ years. OECD
School enrollment	School enrollment, primary, % gross. OECD
Economical Indicators	
GDP	GDP per capita. OECD
Poverty Gap	Of total population. OECD
Poverty Rate	Of total population. OECD
Gender wage gap	Of total population. OECD
Unemployement Rate	Of total population. OECD
Gini Coefficient	OECD
Social Protection	
Social Spending	Cash-benefits, direct in-kind provision of goodds and services, and tax breaks with social purposes. OECD
Sociopolitical indicators of inequality	
Violence Against Women	Prevalence in the lifetime. OECD
Social Institutions and Gender	Discrimination in the family, Restricted access to resources and assets, restricted physical integrity, Restricted civil liberties. OECD, Index

Perceived Health	Of total population. OECD
People at Risk of Poverty or Social Exclusion	Index, Eurostat
Long Hours in Paid Work	Of total population. OECD
Well-Being	
Housing Overcrowding	Of total population. OECD
Social Connections	Social support and satisfaction with personal relationships, OECD
Housing Cost Overburden	Of total population. OECD
Subjective Well-Being	Of total population. OECD
Difficulty making ends meet	Of total population. OECD
Negative affect balance	Of total population. OECD
Work-life balance	Of total population. OECD
Quality of healthcare	
Universal healthcare	Yes/No
Health spendings	As share of GDP. The World Bank
Health coverage	Of total population. OECD
Consultations skipped due to cost	Per 100 patients. OECD
Medical Tests, treatment or follow-up skipped due to costs	Per 100 patients. OECD
Prescribed medicines skipped due to costs	Per 100 patients. OECD
Covid policy measures and downsides of not getting vaccine	
COVID-19 Stringency Index	Oxford Coronavirus Government Response Tracker (OxCGRT), Index

2. Supplementary section 2: Assessment of quality and risk of bias results

Table S1. Risk of bias assessment of included studies (Adapted from Hoy et al)

Author	Was the study´s target population representative?	Was the sample frame a close representation of the target population?	Was the sample randomly selected?	Was the likelihood of non-response bias minimal?	Were data collected directly from the subjects?	Was an acceptable case definition used?	Was the study instrument reliable?	Was the same mode of data collection used for all subjects?	Score
Attwell	No	No	No	Yes	Yes	Yes	Yes	Yes	1
Seale	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Dietze	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Enticott	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Schernhammer	Yes	No	No	Yes	Yes	Yes	Yes	Yes	2
Kessels	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Lavoie	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Basta	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Abramovich	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Manca	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Bagic	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Neumann-Böhme	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Detoc	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	1
Ward	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Montagni	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Ousseine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Coulaud	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Heyerdahl	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Bendau	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Kourlaba	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Murphy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Maor	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	1
Caserotti	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
La Vecchia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Di Giuseppe	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Moscardino	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Palamenghi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Iacoella	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Yoda	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Ihshimaru	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0

Machida	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Kadoya	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sekizawa	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Soares	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Khaled	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Page	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Freeman	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sethi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Freeman	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Batty	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Chaudhuri	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sherman	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sherman	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Earnshaw	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	1
Fisher	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Malik	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	1
Reiter	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	1
Pogue	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	1
Craig	Yes	Yes	No	No	Yes	Yes	Yes	Yes	1
Kelly	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Christodoulou	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sullivan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Stern	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Rogers	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Crozier	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Thunström	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Rane	Yes	Yes	No	No	Yes	Yes	Yes	Yes	2
Scott	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Bogart	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Tucker	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Shaw	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Meehan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0

3. Supplementary section 3: Table S2.Country-specific real-world data

Country	Population	% of population over 65 years	Life expectancy	Date of first vaccine	% of population with complete vaccination as of 31st 2021	Poverty gap	Gender wage gap	% unemployment	% unemployment in migrants	Social spending, %of GDP 2021	Healthcare spending, %GDP	Healthcare coverage	Stringency index at the date of first vaccine
Australia	25690000	16	83.2	22-Feb-21	74								53.24
Austria	8956000	19	81.8	27-Dec-20	71	0.294	14.9	4.9	8.3	31	10.3	99.9	82.41
Belgium	11590000	19	81.7	28-Dec-20	76	0.233	3.4	5.7	10.4	29	10.3	98.6	60.19
Canada	38250000	18	82.0	14-Dec-20	76	0.303	18.5	6.5	6.3	18	10.8	100	72.69
Croatia	3900000	22	77.7	27-Dec-20	49								67.59
Denmark	5857000	20	81.2	27-Dec-20	77	0.289	4.9	5.1	8.4	28.3	10.1	100	51.85
France	67750000	21	82.6	27-Dec-20	73	0.261	11.8	7.9	13.1	33	11.3	100	63.89
Germany	83000000	22	80.9	26-Dec-20	71	0.256	13.9	3.2	5.6	28	11.4	89.5	82.41
Greece	10640000	23	81.9	27-Dec-20	68	0.331	5.9	13.3	28.6	26	7.8	100	84.26
Ireland	5000000	15	82.3	29-Dec-20	77	0.187	8.3	5.1	5.9	14	6.7	100	68.52
Israel	9364000	12	82.8	19-Dec-20	63	0.325	22.7	5	3.4	18	7.5	100	71.3
Italy	59110000	24	83.2	27-Dec-20	76	0.396	5.7	9	13.1	31	8.7	100	78.7
Japan	126000000	30	84.4	17-Feb-21	80	0.364	24.5	2.8	4.2	22.3	10.7	100	49.54
Portugal	10330000	23	80.9	27-Dec-20	83	0.266	22.7	5.9	8.4	25	9.4	100	63.89
Qatar	2660000	1	79.1	31-Jan-21	82								64.81
Switzerland	8703000	19	83.7	23-Dec-20	67	0.281	18	2.6	7,3	18	11.9	100	60.19
UK	67330000	18	81.2	08-Dec-20	70	0.326	16.3	3.9	4.3	22	10.2	100	63.89
USA	332000000	17	77.2	14-Dec-20	63	0.368	18.9	8.09	3.1	23	16.9	91.4	71.76

4. Supplementary section 4: Country-specific analyses

Random-effects meta-analysis of COVID-19 vaccine acceptance in Australia

a. All the studies from Australia



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from Australia according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is

centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in Canada

a. All the studies from Canada



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from Canada according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in France

a. All the studies from France



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from France according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in Italy

a. All the studies from Italy



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from Italy according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in Japan



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in the United Kingdom



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in the United States

a. All the studies from the U.S



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from the U.S according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

5. Supplementary section 5: Comparison between data from studies and real-world data

a. Table S3. Willingness to be vaccinated and real-world vaccine uptake

Country	% (CI 95%) of the general population willing to be vaccinated before vaccines rollout*	% (CI 95%) of special populations willing to be vaccinated before vaccines rollout*	% of the general population with complete vaccination as of 31st Dec 2021**	Difference between willingness and uptake
Australia	70 (58-79)	48 (27-70)	74	+4
Austria	36 (33-39)	-	71	+35
Belgium	34 (32-36)	-	76	+42
Canada	73 (42-91)	64 (32-87)	76	+3
Croatia	64 (60-67)		49	-15
Denmark	80 (79-81)	-	77	-3
France	69 (59-77)	61 (37-80)	73	+4
Germany	64 (62-67)	-	71	+7
Greece	58 (55-61)	-	68	+10
Ireland	65 (62-68)	-	77	+12
Israel	76 (74-78)	-	63	+7
Italy	67 (55-77)	64 (46-78)	76	+9
Japan	55 (42-67)	-	80	+25
Portugal	35 (33-37)	-	83	+48
Qatar	43 (40-45)		82	+39
Switzerland	-	41	67	-
UK	75 (63-84)	-	70	+5
USA	71 (63-78)	50 (39-61)	63	-8

*From the results of the systematic review.
**https://ourworldindata.org

b. Consolidated country data from studies and country real-world statistics





6. Supplementary section 6: Sensitivity analyses

a. Outlier and influential case diagnostics



rstudent= externally standardized residuals, dffits= difference in fit values, cook.de=Cook's distances, cov.r= covariance ratios, tau2.del= leave-one-out estimates of the amount of heterogeneity, QE.del= leave-one-out values of the test statistics for heterogeneity, hat= hat values, weight= weights

b. Cumulative meta-analysis of willingness to be vaccinated according to the date of data acquisition. General population.



c. Cumulative meta-analysis of willingness to be vaccinated according to the date of data acquisition. Special populations.



d. Cumulative real-world data meta-analysis according to the date of first COVID-19 vaccine administered in each country



e. Results from the generalized linear models for vaccine uptake and country-level data

	B	Standard error	p-value	OR	95% CI
Intercept	80.683	10.35	.000		
Stringency index	-.206	.10	.04	.81	(0.69-0.94)
% of the population older than 65 years	.595	.28	.03	1.8	(1.04-3.1)
Healthcare spending as % of GDP	-.997	.46	.03	0.36	(0.14-0.91)
Social spending as % of GDP	.183	.21	.4	1.2	(0.78-1.84)

f. Bubble plots from meta-regressiosn analyses to explore associations of country-level data with vaccine uptake

Stringency index



Percentage of the population older than 65 years



Healthcare spending as a percentage of GDP



g. Random-effects meta-analysis of COVID-19 vaccine acceptance in the general population for studies with high risk of selection bias



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

7. Supplementary section 7 PRISMA checklist

Prisma 2020 Checklist

Abstract checklist	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Yes
Synthesis of results	6	Specify the methods used to present and synthesise results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	No
Registration	12	Provide the register name and registration number.	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1, title
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Abstract
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Methods section, pages 5,6
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Supplementary section 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplementary section 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary section 1|
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Supplementary section 1
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Methods section, page 6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Supplementary section 1

Section and Topic	Item #	Checklist item	Location where item is reported
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary section 1
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Data synthesis, page 7
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Data synthesis, page 7
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Sensitivity analyses, page 8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Sensitivity analyses, page 8
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	NA
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure S1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Supplementary material, section 1c

Section and Topic	Item #	Checklist item	Location where item is reported
Study characteristics	17	Cite each included study and present its characteristics.	Results section, page 8 and Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table S1
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 1, Figure 2.
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Supplementary section 3,
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Results section, pages 8-11
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Results section, page 10. Supplementary section 6
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Supplementary section 6
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Main findings, page 11
	23b	Discuss any limitations of the evidence included in the review.	Study limitations, page 13

Section and Topic	Item #	Checklist item	Location where item is reported
	23c	Discuss any limitations of the review processes used.	-
	23d	Discuss implications of the results for practice, policy, and future research.	Findings in context, page 13
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	The review was not registered because it was a realist review
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 1
Competing interests	26	Declare any competing interests of review authors.	Page 1
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Supplementary material

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
For more information, visit: http://www.prisma-statement.org/

Prisma 2020 Checklists

Abstract checklist	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Yes
Synthesis of results	6	Specify the methods used to present and synthesise results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	No
Registration	12	Provide the register name and registration number.	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1, title
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Abstract
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Methods section, pages 5,6
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Supplementary section 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplementary section 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary section 1|
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Supplementary section 1
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Methods section, page 6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Supplementary section 1
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary section 1
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Data synthesis, page 7
Synthesis	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics	

Section and Topic	Item #	Checklist item	Location where item is reported
methods		and comparing against the planned groups for each synthesis (item #5)).	
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Data synthesis, page 7
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Sensitivity analyses, page 8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Sensitivity analyses, page 8
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	NA
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure S1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Supplementary material, section 1c
Study characteristics	17	Cite each included study and present its characteristics.	Results section, page 8 and Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table S1
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 1, Figure 2.
Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Supplementary

Section and Topic	Item #	Checklist item	Location where item is reported
syntheses			section 3,
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Results section, pages 8-11
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Results section, page 10. Supplementary section 6
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Supplementary section 6
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Main findings, page 11
	23b	Discuss any limitations of the evidence included in the review.	Study limitations, page 13
	23c	Discuss any limitations of the review processes used.	-
	23d	Discuss implications of the results for practice, policy, and future research.	Findings in context, page 13
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	The review was not registered because it was a realist review
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA

Section and Topic	Item #	Checklist item	Location where item is reported
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 1
Competing interests	26	Declare any competing interests of review authors.	Page 1
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Supplementary material

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
For more information, visit: http://www.prisma-statement.org/

BMJ Open

Realist review of COVID-19 vaccine acceptance in the general population and under-resourced communities from high-income countries.

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2024-084560.R1
Article Type:	Original research
Date Submitted by the Author:	26-Mar-2024
Complete List of Authors:	Gonzalez-Jaramillo, Nathalia; University of Bern, ISPM Abbühl, Dominik; University of Bern, ISPM; University of Bern, Faculty of Medicine Roa-Díaz, Zayne; University of Bern Kobler-Betancourt, Cristopher; University of Bern Frahsa, Annika; University of Bern
Primary Subject Heading:	Public health
Secondary Subject Heading:	Infectious diseases, Public health, Global health, Epidemiology
Keywords:	COVID-19, Meta-Analysis, Vaccination

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Realist review of COVID-19 vaccine acceptance in the general population and under-resourced communities from high-income countries.

Gonzalez-Jaramillo Nathalia, MD,PhD,[1] Abbühl Dominik, MD,[1,2] Roa-Díaz Zayne Milena, RN,PhD,[3] Kobler-Betancourt Cristopher, [1] Frahsa Annika, PhD.[1]

1 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

2 Faculty of Medicine, University of Bern, Bern, Switzerland.

3. Medical Library, University library of Bern, University of Bern, Bern, Switzerland

Word count:

Abstract word count:

Declaration of funding

Conflicts of interest / financial disclosures: The authors have no conflicts of interest to declare that are relevant to the content of this article.

Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination plans of our research.

Acknowledgments:

We thank the Lindenhof Foundation for their financial support of our research group. We thank Kristin Marie Bivens for her editorial work and guidance on our manuscript.

Corresponding authors / Reprint requests:

Nathalia Gonzalez-Jaramillo. Email: nathalia.gonzalez-jaramillo@cslbehring.com

Annika Frahsa. University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland. annika.frahsa@unibe.ch

Institute of Social and Preventive Medicine, University of Bern, Switzerland.

Mittelstrasse 43

3012 Bern, Switzerland . Direct dial: +41 31 684 56 79

ORCIDs:

Nathalia Gonzalez: 0000-0003-4975-4439

Annika Frahsa: 0000-0002-0207-3989

Abstract

Objective

To compare vaccination willingness before roll-out and one-year post-rollout uptake among the general population and under-resourced communities in High income countries.

Design

A realist review

Data sources

Embase, PubMed, Dimensions ai, and Google Scholar

Setting

High-income countries

Definitions

We defined *vaccination willingness* as the proportion of participants willing or intending to receive vaccines prior to availability. We defined vaccine uptake as the real proportion of the population with complete vaccination as reported by each country until November 2021.

Results

We included data from 62 studies and 18 HIC. For studies conducted among general populations, the proportion of vaccination willingness was 67% [95% confidence interval (CI) 62%–72%]. In real-world settings, the overall proportion of vaccine uptake among those countries was 73% (CI 69%–76%). 17 studies reported pre-rollout willingness for under-resourced communities. The summary proportion of vaccination willingness from studies reporting results among people from under-resourced communities was 52% (95% CI 0.46–0.57). Real-world evidence about vaccine uptake after rollout among under-resourced communities was limited.

Conclusion

Our review emphasizes the importance of realist reviews for assessing vaccine acceptance. Limited real-world evidence about vaccine uptake among under-resourced communities in high-income countries is a call to context-specific actions and reporting.

Strengths and limitations of this study

- For country vaccination willingness we included only studies with national representative samples.
- For under-resourced communities' vaccination willingness, we included studies with purposive samples.
- We compared countries' vaccination willingness with official country-level national reports.
- Official country-level reports about uptake among under-resourced communities were limited.
- We could not compare vaccination willingness with real-world vaccine uptake statistics among under-resourced communities.

Introduction

Cumulative excess death from the coronavirus disease (COVID-19) pandemic made it a leading global cause of death between 2020–2021.(1) Universal vaccination played a significant role transitioning into post-pandemic life.(2) COVID-19 vaccines were developed and authorized in record time; as of April 2023, 70% of the world population received at least one COVID-19 vaccine dose. However, vaccine uptake is complicated; it involves more than simply making vaccines available. For instance, inequitable vaccine distribution possibly contributes to the 2.8-fold difference in vaccine coverage between high- and low-income countries.(3) Whereas vaccine uptake in high-income countries (HIC) was 81%, vaccine uptake in low-income countries (LIC) was 29%.(4)

Countries with strong public health systems and economic resources achieved some early success vaccinating populations, yet people from historically, socially, or economically under-resourced communities, such as people who experience homelessness, people from ethnic and racial minorities, as well as people with immigration or refugee experience, possibly remained unvaccinated for complex

reasons. Regarding vaccination willingness and uptake among people from ethnic minority groups, Raizai et al.(5, 6) identified several structural aspects resulting from a mistrust of government and public health bodies: systemic racism and discrimination at societal and healthcare system levels, histories of unethical studies, as well as underrepresentation of people from ethnic and racial minority groups in health, drug, and vaccine trials. Distrust in medical institutions from inappropriate care and mistreatment also impacted vaccination willingness among people from socially or economically under-resourced communities, such as members of indigenous communities or racial minority groups as well as among incarcerated individuals. (7), (8, 9)

Additionally, local barriers to access vaccinations and individual vaccine hesitancy played roles explaining vaccine uptake differences within and among countries.(3) Notwithstanding, structural access barriers and individual vaccine hesitancy possibly share common pathways, which complicates disentangling their effects in vaccination uptake.(10) For instance, in a systematic review of barriers, facilitators, and vaccine hesitancy with included studies about mainly HIC, they found individuals from minority ethnic groups concurrently experience more access barriers along with higher vaccine hesitancy and lower vaccine uptake when compared with individuals from majority ethnic groups and non-migrants.(11) Therefore, a debate is ongoing about the true proportion of hesitancy and vaccine refusal among unvaccinated individuals in HIC. Although individual vaccination willingness is not under discussion, understandings about vaccination willingness and vaccine uptake possibly inform health policies more reliably, identify access barriers to vaccines, facilitate vaccination campaign planning, and enhance uptake, eventually.

Generally, marginalization and vaccine uptake in HIC has been scarcely described in the literature. We performed a realist synthesis to evaluate COVID-19 vaccine acceptance and its determinants among people from under-resourced communities in HIC. We compared data collected from a specific systematic review with real-world statistics to study the general evolution of vaccination rates—from hypothetical acceptance before the widespread rollout of vaccination programs—until December 2021, one year after the first vaccine was available and when presumably, most HIC populations could be vaccinated. In addition, we compared hypothetical vaccination willingness between the general population and under-resourced communities in HIC.

Methods

Study design and sources of data

We conducted a quantitative realist synthesis on the prevalence of vaccine acceptance among the general population from HIC. We followed the realist and meta-narrative evidence syntheses (RAMESES) quality and publication standards and reporting guidelines.(12) We also report our findings according to the statement on preferred reporting items for systematic reviews and meta-analyses(13) (PRISMA). We defined *vaccination willingness* as the proportion of participants willing or intending to receive a vaccine before vaccines were available. We defined *vaccine uptake* as the real proportion of the population with complete vaccination as reported by each country until November 2021.

A medical information specialist searched three electronic databases: PubMed, Embase, and Dimensions ai. For informal sources, and to add possibly relevant articles where the search terms only appear in the full text of an article, we also screened the first 200 hits of a Google Scholar search. The detailed search strategy

is available in the Section 1 from the supplementary material. We sought peer-review scientific literature published before November 30, 2022. Different descriptors were used for each component of the search. for surveys investigating COVID-19 vaccine attitudes among adult populations from HIC before COVID-19 vaccine roll-out. We used the World Bank database to classify countries of origin according to income at the time of data collection [US$12,536 or more gross national income (GNI) per capita in 2019]. We defined the study to include surveys reporting quantitative data on populations willing to be vaccinated when vaccines became available. We included surveys meeting the following criteria: 1) conducted in 2020–2021 among adult populations before vaccine rollout campaigns; 2) reported prevalence of vaccination willingness via questionnaires; 3) peer-reviewed; 4) performed probabilistic sampling; and 5) reported results for general populations and/ or under-resourced communities. To mitigate the risk of bias, for country vaccination willingness we included only studies with national representative samples. For under-resourced communities' vaccination willingness, we also included studies with purposive samples.

We excluded studies of unrepresentative participants from general populations, such as people with particular conditions or health statuses—like people with diabetes or pregnant people—or particular occupations—like health care workers or university students. We excluded articles with incomplete information, systematic reviews and meta-analyses, and reports from meetings or congresses.

We provide details for our study selection and data extraction methods in Supplementary section 1. When multiple records included data from the same country, we extracted data from all of them and calculated country-specific pooled prevalence and used the pooled prevalence as the value to compare further with real-world statistics of vaccine uptake.

Study outcomes

For each country, outcomes of interest included 1) the proportion of people willing to be vaccinated according to results of the systematic review (primary outcome: vaccination willingness/acceptance); and 2) the proportion of vaccinated people according to the real-world data statistics (secondary outcome: vaccine uptake).

Data selection and extraction

Two reviewers independently screened all records and verified included and excluded studies by using REDCap (Vanderbilt University, Nashville, TN, USA). We report identification, exclusion, and inclusion of studies in the Figure S1 flow diagram. One reviewer extracted data using a pre-piloted extraction form, and a second reviewer verified the extracted data. Extracted variables included, yet were not limited to sample size, study design, publication date, survey date, country and study population composition, community type, age, vaccine hesitancy, vaccine acceptance, and vaccine refusal (Supplementary section 1.d). We extracted all proportions as reported. For the realist synthesis, we obtained available country-specific data from multiple sources.(14, 15) We provide sources of information and definitions for country-specific variables in Supplementary section 1.d.

Patient and public involvement

Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination plans of our research.

Potential bias assessment

Two independent reviewers assessed the risk of bias for each study using the checklist for prevalence studies from Hoy et al; we assessed each question independently and calculated scores, as recommended by checklist developers.(16) However, we did not use total scores in analyses. Instead, we grouped questions into

categories according to the bias domain they addressed.(17) We analyzed risk of selection bias and risk of nonresponse bias as potential sources of heterogeneity among studies. We provide potential bias assessment results in Supplementary section 2. Table S1.

Statistical analysis

Data synthesis

We estimated the pooled prevalence of vaccination willingness and 95% confidence intervals (CI) using random effects models. We used the 'metaprop' function from the 'meta' package in R (version 3.5.1) to synthesize and display findings from included studies in forest plots. For overall summary estimates, we calculated prediction intervals to represent the likely range of proportions obtained in subsequent studies conducted in similar settings.(18) We quantified statistical heterogeneity using the I^2 statistic. Heterogeneity was classified according to the most recent version of the Cochrane Handbook: 0–40% might not be important; 30–60% may represent moderate heterogeneity; 50–90% may represent substantial heterogeneity; 75– 100% considerable heterogeneity. However, in meta-analyses of prevalence, heterogeneity according to the I^2 statistic is expected to be substantial and possibly not discriminative.(19) Therefore, we also calculated prediction intervals to describe the expected range of estimates.

Sensitivity analyses

We performed sensitivity analyses. First, we used the influence function in the 'metafor' package to compute outliers and influential case diagnostics, including externally standardized residuals and leave-one-out estimates of heterogeneity. Second, we investigated the impact of selection bias as a potential source of heterogeneity by means of meta-regression.

Real-world data analysis

After synthesizing information from included studies, we compared results for each country with real-world data statistics concerning vaccination uptake. In addition, we identified how different country characteristics and policies (Supplementary section 3, Table S2) in each country could be associated with vaccination uptake. Specifically, we selected four components to examine separately: percentage of populations older than 65 years; social spending as a percentage of gross domestic product (GDP); healthcare spending as a percentage of GDP; and stringency index (Oxford COVID-19 Government Response Tracker index) at the start date of vaccine rollout campaigns in each country since we thought them most likely associated with vaccine uptake among general populations.(14)

Results

After deduplication, we identified 3349 potentially relevant citations. After initial screening based on titles and abstracts, we selected full texts of 214 articles for detailed evaluation (Figure S1). After full-text assessment, we excluded 152 citations. We provide the complete list of excluded references and reasons for exclusion in the Supplementary section 1c. We included the remaining 62 articles that reported vaccination willingness before vaccine rollout at the country-level.

General characteristics of included studies.

We provide detailed characteristics of included studies in Table 1. Overall, studies included 299,769 individuals from 18 HIC. Among the 62 included references, 45 studies reported results for general populations and 17 studies reported results for at least one under-resourced community. We calculated the weighted average of exported mean ages from each study; the mean age was 47.5 years. The proportion of women ranged from 16% to 93% among studies including patients from both sexes.

Two studies reported including only men.(20, 21) Study sample sizes conducted among general populations ranged from 316 to 63,266 and study sample sizes conducted among under-resourced communities ranged from 83 to 18,474.

Since reporting vaccination willingness via questionnaire was an inclusion criteria, all studies used validated questionnaires or questionnaires developed specifically for studies.

General characteristics of the included countries

We present detailed characteristics of included countries in Table S2. Country populations ranged between 2.6 million (Qatar) and 332 million (United States). Median population was 11.1 million [interquartile range (IQR): 7.9–67]. Median percentage of populations older than 65 years was 19 (IQR: 16.8–22.2), and median value for life expectancy was 81.5 years (IQR: 81–83). With respect to economic indicators related to public policy, median social spending as a percentage of GDP was 25 (IQR: 18–29); median healthcare spending as a percentage of GDP was 10.3 (IQR: 8.7–11.3). We determined two median indicators of inequality: poverty gap 0.29 (IQR: 0.26–0.33) and gender wage gap 15 (IQR: 6–19), respectively.

Proportion of people from general populations reporting vaccination willingness before vaccine rollout

Among general populations, the summary proportion of vaccination willingness (Figure 1) was estimated across all study settings as 67% (95% CI 61%–72%, 45 studies). Forty-five studies reported vaccine acceptance among general populations: Australia (3 studies);(22-24) Austria (1 study);(25) Canada (2 studies);(26, 27) Croatia (1 study);(28) Denmark (1 study);(29) France (5 studies);(30-34) Germany (1 study);(35) Greece (1 study);(36) Ireland (1 study);(37) Israel (1 study);(38) Italy (4 studies);(39-42) Japan (5 studies);(43-47) Portugal (1 study);(48) Qatar (1 study);(49)

Switzerland(1 study);(50) United Kingdom (7 studies);(51-57) and the United States (9 studies).(58-66)

Proportion of people from under-resourced communities reporting vaccination willingness before vaccine rollout

The summary proportion of vaccination willingness for studies conducted among people from under-resourced communities (Figure 2) was estimated as 52% (95% CI 0.46–0.57, 17 studies). The seventeen studies reporting vaccine acceptance in under-resourced communities included four studies among people experiencing homelessness;(67-70) two studies among people using illicit and unprescribed drugs;(71, 72) three studies among lesbian, gay, bisexual, and transgender populations;(21, 73, 74) two studies among incarcerated populations;(20, 75) two studies among refugee and undocumented migrant populations;(50, 76) and one study for each one of the following: indigenous population;(9) a rural community ;(77) a Latino population;(78) and a Black American population.(7) In the cumulative meta-analysis from sensitivity analyses, we found a trend towards acceptance according to dates of data acquisition ranging from 32% in early pandemic stages to 52% during late pandemic stages before vaccine rollout (Supplementary section 5.c)

Proportion of vaccine uptake from real-world country statistics one year after vaccine rollout

The summary proportion of vaccine uptake from included countries was estimated as 73% (95% CI 0.69–0.76, 18 countries). In general, the proportion of vaccine uptake for each country was higher than vaccination willingness before vaccine rollout (Supplemental material, Table S3), except for Croatia (-15%), Denmark (-3%), and the United States (-8%). In the cumulative meta-analysis, we did not observe an effect from date of vaccine approval on vaccine uptake at the end of 2021 (Supplementary section 6). However, in meta-regression analyses (Supplementary

section 6. Sensitivity analyses) vaccine uptake increased according to the proportion of the population older than 65 years [odds ratio (OR)=1.8, 95%CI 1.04–3.1] and decreased at higher stringency index values (OR=0.8, 95%CI 0.69–0.94).

Discussion

Main findings

Our realist synthesis involves data from 62 studies and 18 countries; we contribute to knowledge about the prevalence of vaccine acceptance among general populations and people from under-resourced communities. Additionally, we compared proportions of expected vaccine uptake from studies conducted before vaccines were available with the real uptake from the end of December 2021. To our knowledge, ours is the first systematic and realist review comparing vaccination willingness and vaccine uptake using real-world statistics among general populations with people from under-resourced communities in HIC.

The countries included in the study represented 70% of the high-income country world population. Most countries showed higher vaccine uptake compared to the reported vaccination willingness in studies conducted before the vaccine rollout. For all studies among general populations, the proportion of vaccination willingness was 67% (95% CI 62%–72%). In real-world settings, the overall proportion of vaccine uptake among countries was 73% (CI 69%–76%). However, the scope of this study is limited in exploring possible explanations for lower-than-expected rates of vaccine uptake in Croatia, Denmark, and the United States. For all the other countries, the real-world uptake was consistently higher than the reported willingness before rollout.

It is worth noting that some studies not included in our meta-analysis that evaluated the willingness to receive the vaccine when the vaccination rollout had

already started in their country may have reported higher rates of willingness to receive the vaccine compared to the country´s real uptake.(79) However, this should not be interpreted as an overestimation since such willingness was estimated on the unvaccinated fraction of the population instead of the total population of the country who was completely unvaccinated only before the rollout.

The pooled proportion from studies reporting vaccination willingness among under-resourced communities before rollout was 52% (95% CI 0.46–0.57). Official country-level reports about vaccine uptake among under-resourced communities was too limited so we could not compare vaccination willingness before rollout with real-world uptake statistics among under-resourced communities after vaccine rollout.

Findings in context

The proportion of vaccination willingness among people from under-resourced communities was consistently lower than the proportion of vaccination willingness among people from populations in total. Existing evidence suggest people from ethnic minority groups(7) and indigenous communities reasonably distrust medical institutions from experiences of differential care and mistreatment.(8, 9) Mistrust of institutions and governments was reported as the most common reason to delay vaccine uptake among ethnic minority groups,(7) indigenous communities (8, 9), and incarcerated people.(75) Experiences of discrimination, stigma, and barriers to access were reported as possible explanations for lower prevalence of vaccine acceptance among people from sexual and gender minority groups.(80)

Despite the lack of official data on real-world uptake among under-resourced communities, some studies have reported lower vaccine uptake compared to the general population. For instance, a study among healthcare workers in the UK found that vaccine uptake was 58.5% among South Asian and 36.8% among Black ethnic

minority groups, compared to 70% in white healthcare workers.(81) Another analysis of patient primary care records in the UK found lower vaccine uptake among different ethnic groups (Black 68%, White 96%) and to and to a lesser extent, among different levels of deprivation (most deprived 91%, least deprived 97%). (82)

Recent evidence provides initial insights about overcoming barriers to vaccination uptake. For instance, multi-component interventions with tailored communication of risks of remaining unvaccinated and benefits of becoming vaccinated,(83) community-based action and engagement of religious and community leaders, dialogue to understand reasons for mistrust in government and public health bodies, as well as well as provision of access to convenient vaccination in collaboration with community-based and trusted health institutions.(84)

We suggest future studies compare trajectories of vaccination willingness with vaccine uptake among under-resourced communities. We also recommend future research link findings of trajectories with context-specific actions to address barriers to vaccine uptake among people from under-resourced communities. Ultimately, more research is needed to better understand vaccine uptake and the joint interactions among barriers, unwillingness, hesitancy, postponement, or other unknown aspects driving vaccine uptake. The identification of necessary adjustments needed to improve vaccination uptake among different groups may inform future vaccination programs.

Strengths and limitations

Studies reporting prevalence served as important sources of evidence during the COVID-19 pandemic and helped researchers understand factors related to the disease and inform policies. However, prevalence estimates from individual studies and pooled prevalence estimates from our meta-analyses may have been affected by selection and reporting biases.(17) Notwithstanding, our inclusion criteria attempted

to reduce such risks of bias, and we performed multiple sensitivity analyses that provided insights into possible sources of heterogeneity. A strength of the realist approach is the use of diverse sources of information. In the specific context of COVID-19 vaccine acceptance, the fact that countries have reporting systems in place to keep population-based statistics made it possible to assess the real-life counterpart of the studies.(85)

Conclusion

Our systematic and realist review highlights COVID-19 vaccine uptake in HIC generally exceeded expressed vaccination willingness before vaccine rollout and vaccination willingness tended to be lower among under-resourced communities, when compared with total populations living in HIC. Our review emphasizes the importance of realist reviews for assessing vaccine acceptance and particularly the need for more specific real-world statistics on vaccine uptake among under-resourced communities as well as the importance of context-specific actions to promote vaccine uptake and reporting.

Data availability statement

All data relevant to the study are included in the article or uploaded as online supplemental information.

Authors' contributions

NGJ and AF conceived the research idea and planned the work, ZR conducted the search, DA and NG screened the papers and extracted the data, NGJ analyzed the results, NGJ, and AF jointly wrote the report, CB, DA, and ZR, revised the report.

Figures and captions:

1. **Title :**Figure 1. Random-effects meta-analysis of COVID-19 vaccine acceptance in the general population.

Caption: For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

2. **Title :** Figure 2. Random-effects meta-analysis of COVID-19 vaccine acceptance in special populations

Caption: For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

References

1. Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. JAMA. 2021;325(18):1829-30.

2. Biancolella M, Colona VL, Mehrian-Shai R, Watt JL, Luzzatto L, Novelli G, Reichardt JKV. COVID-19 2022 update: transition of the pandemic to the endemic phase. Human Genomics. 2022;16(1):19.

3. Bayati M, Noroozi R, Ghanbari-Jahromi M, Jalali FS. Inequality in the distribution of Covid-19 vaccine: a systematic review. International Journal for Equity in Health. 2022;21(1):122.

4. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nature Human Behaviour. 2021;5(7):947-53.

5. Razai MS, Osama T, McKechnie DGJ, Majeed A. Covid-19 vaccine hesitancy among ethnic minority groups. BMJ (Clinical research ed). 2021;372:n513.

6. Razai MS, Kankam HKN, Majeed A, Esmail A, Williams DR. Mitigating ethnic disparities in covid-19 and beyond. BMJ (Clinical research ed). 2021;372:m4921.

7. Bogart LM, Dong L, G, Hi P, Klein DJ, Smith TL, et al. COVID-19 Vaccine Intentions and Mistrust in a National Sample of Black Americans. Journal of the National Medical Association. 2022;113(6):599-611.

8. Mosby I, Swidrovich J. Medical experimentation and the roots of COVID-19 vaccine hesitancy among Indigenous Peoples in Canada. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2021;193(11):E381-e3.

9. Manca T, Humble RM, Aylsworth L, Cha E, Wilson SE, Meyer SB, et al. "We need to protect each other": COVID-19 vaccination intentions

and concerns among Racialized minority and Indigenous Peoples in Canada. Social science & medicine (1982). 2022;313:115400.

10. Njoku A, Joseph M, Felix R. Changing the Narrative: Structural Barriers and Racial and Ethnic Inequities in COVID-19 Vaccination. International journal of environmental research and public health. 2021;18(18).

11. Abba-Aji M, Stuckler D, Galea S, McKee M. Ethnic/racial minorities' and migrants' access to COVID-19 vaccines: A systematic review of barriers and facilitators. Journal of migration and health. 2022;5:100086.

12. Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: realist syntheses. BMC Medicine. 2013;11(1):21.

13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed). 2021;372:n71.

14. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav. 2021;5(4):529-38.

15. Data TWB. 2020 [Nov 2022].

16. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. Journal of clinical epidemiology. 2012;65(9):934-9.

17. Diana B-G, Georgia S, Nicola L. Studies of prevalence: how a basic epidemiology concept has gained recognition in the COVID-19 pandemic. BMJ Open. 2022;12(10):e061497.

18. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ (Clinical research ed). 2011;342:d549.

19

19. Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, Falavigna M. Meta-analysis of prevalence: I(2) statistic and how to deal with heterogeneity. Research synthesis methods. 2022;13(3):363-7.

20. Di Giuseppe G, Pelullo CP, Lanzano R, Napolitano F, Pavia M. Knowledge, attitudes, and behavior of incarcerated people regarding COVID-19 and related vaccination: a survey in Italy. Scientific reports. 2022;12(1):960.

21. Ousseine YM, Vaux S, V, Entorren S, Bonmarin I, Champenois K, et al. Predictors of Uncertainty and Unwillingness to Receive the COVID-19 Vaccine in Men Who Have Sex with Men in France. International journal of environmental research and public health. 2022;19(9).

22. Attwell K, Lake J, Sneddon J, Gerrans P, Blyth C, Lee J. Converting the maybes: Crucial for a successful COVID-19 vaccination strategy. PloS One. 2021;16(1):e0245907.

23. Seale H, Heywood AE, Leask J, Sheel M, Durrheim DN, Bolsewicz K, Kaur R. Examining Australian public perceptions and behaviors towards a future COVID-19 vaccine. BMC infectious diseases. 2021;21(1):120.

24. Enticott J, Gill JS, Bacon SL, Lavoie KL, Epstein DS, Dawadi S, et al. Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis-implications for public health communications in Australia. BMJ open. 2022;12(1):e057127.

25. Schernhammer E, Weitzer J, Laubichler MD, Birmann BM, Bertau M, Zenk L, et al. Correlates of COVID-19 vaccine hesitancy in Austria: trust and the government. Journal of Public Health (Oxford, England). 2022;44(1):e106-e16.

26. Basta NE, Sohel N, Sulis G, Wolfson C, Maimon G, Griffith LE, et al. Factors Associated With Willingness to Receive a COVID-19 Vaccine Among 23,819 Adults Aged 50 Years or Older: An Analysis of the Canadian Longitudinal Study on Aging. American journal of epidemiology. 2022;191(6):987-98.

27. Lavoie K, Gosselin-Boucher V, Stojanovic J, Gupta S, Gagne M, Joyal-Desmarais K, et al. Understanding national trends in COVID-19 vaccine hesitancy in Canada: results from five sequential cross-sectional representative surveys spanning April 2020-March 2021. BMJ open. 2022;12(4):e059411.

28. Bagic D, Suljok A, Ancic B. Determinants and reasons for coronavirus disease 2019 vaccine hesitancy in Croatia. Croatian medical journal. 2022;63(1):89-97.

29. Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. The European journal of health economics: HEPAC: health economics in prevention and care. 2020;21(7):977-82.

30. Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, Gagneux-Brunon A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020;38(45):7002-6.

31. Montagni I, Ouazzani-Touhami K, Pouymayou A, Pereira E, Texier N, Schuck S, et al. Who is hesitant about Covid-19 vaccines? The profiling of participants in a French online cohort. Revue d'epidemiologie et de sante publique. 2022;70(3):123-31.

32. Ward JK, Alleaume C, Peretti-Watel P, Group C. The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue. Social science & medicine (1982). 2020;265:113414.
33. Coulaud P-J, Ablona A, Bolduc N, Fast D, Bertr, Karine, et al. COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France. Vaccine. 2022;40(16):2442-56.
34. Heyerdahl LW, Vray M, Lana B, Tvardik N, Gobat N, Wanat M, et al. Conditionality of COVID-19 vaccine acceptance in European countries. Vaccine. 2022;40(9):1191-7.
35. Bendau A, Plag J, Petzold MB, Ströhle A. COVID-19 vaccine hesitancy and related fears and anxiety. International Immunopharmacology. 2021;97:107724.
36. Kourlaba G, Kourkouni E, Maistreli S, Tsopela C-G, Molocha N-M, Triantafyllou C, et al. Willingness of Greek general population to get a COVID-19 vaccine. Global Health Research and Policy. 2021;6(1):3.
37. Murphy J, Vallières F, Bentall RP, Shevlin M, McBride O, Hartman TK, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nature Communications. 2021;12(1):29.
38. Maor Y, Caspi S. Attitudes towards influenza, and COVID-19 vaccines during the COVID-19 pandemic among a representative sample of the Jewish Israeli population. PloS one. 2022;17(2):e0255495.
39. Caserotti M, Girardi P, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents. Social science & medicine (1982). 2021;272:113688.

40. La Vecchia C, Negri E, Alicandro G, Scarpino V. Attitudes towards influenza vaccine and a potential COVID-19 vaccine in Italy and differences across occupational groups, September 2020. La Medicina Del Lavoro. 2020;111(6):445-8.

41. Moscardino U, Musso P, Inguglia C, Ceccon C, Miconi D, Rousseau C. Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy. Vaccine. 2022;40(16):2379-87.

42. Palamenghi L, Barello S, Boccia S, Graffigna G. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. European Journal of Epidemiology. 2020;35(8):785-8.

43. Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, et al. Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. Human Vaccines & Immunotherapeutics. 2021;17(11):3975-81.

44. Machida M, Nakamura I, Kojima T, Saito R, Nakaya T, Hanibuchi T, et al. Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic. Vaccines. 2021;9(3):210.

45. Kadoya Y, Watanapongvanich S, Yuktadatta P, Putthinun P, Lartey ST, Khan MSR. Willing or Hesitant? A Socioeconomic Study on the Potential Acceptance of COVID-19 Vaccine in Japan. International journal of environmental research and public health. 2021;18(9):4864.

46. Sekizawa Y, Hashimoto S, Denda K, Ochi S, So M. Association between COVID-19 vaccine hesitancy and generalized trust, depression, generalized anxiety, and fear of COVID-19. BMC public health. 2022;22(1):126.

47. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan. Vaccines. 2021;9(1):48.

48. Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors Associated with COVID-19 Vaccine Hesitancy. Vaccines. 2021;9(3):300.

49. Khaled SM, Petcu C, Bader L, Amro I, Al-Hamadi AMHA, Al Assi M, et al. Prevalence and Potential Determinants of COVID-19 Vaccine Hesitancy and Resistance in Qatar: Results from a Nationally Representative Survey of Qatari Nationals and Migrants between December 2020 and January 2021. Vaccines. 2021;9(5):471.

50. Page KR, Genovese E, Franchi M, Cella S, Fiorini G, Tlili R, et al. COVID-19 vaccine hesitancy among undocumented migrants during the early phase of the vaccination campaign: a multicentric cross-sectional study. BMJ open. 2022;12(3):e056591.

51. Batty GD, Deary IJ, Altschul D. Pre-pandemic mental and physical health as predictors of COVID-19 vaccine hesitancy: evidence from a UK-wide cohort study. Annals of medicine. 2022;54(1):274-82.

52. Freeman D, Loe BS, Chadwick A, Vaccari C, Waite F, Rosebrock L, et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychological Medicine. 2020:1-15.

53. Freeman D, Waite F, Rosebrock L, Petit A, Causier C, East A, et al. Coronavirus conspiracy beliefs, mistrust, and compliance with government guidelines in England. Psychological Medicine. 2022;52(2):251-63.

54. Sethi S, Kumar A, Mandal A, Shaikh M, Hall CA, Kirk JMW, et al. The UPTAKE study: a cross-sectional survey examining the insights and

beliefs of the UK population on COVID-19 vaccine uptake and hesitancy. BMJ Open. 2021;11(6):e048856.

55. Chaudhuri K, Chakrabarti A, Ch, An JS, B, Yopadhyay S. COVID-19 vaccine hesitancy in the UK: a longitudinal household cross-sectional study. BMC public health. 2022;22(1):104.

56. Sherman SM, Sim J, Cutts M, Dasch H, Amlot R, Rubin GJ, et al. COVID-19 vaccination acceptability in the UK at the start of the vaccination programme: a nationally representative cross-sectional survey (CoVAccS - wave 2). Public health. 2022;202:1-9.

57. Sherman SM, Smith LE, Sim J, Amlôt R, Cutts M, Dasch H, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Human Vaccines & Immunotherapeutics. 2021;17(6):1612-21.

58. Earnshaw VA, Eaton LA, Kalichman SC, Brousseau NM, Hill EC, Fox AB. COVID-19 conspiracy beliefs, health behaviors, and policy support. Translational Behavioral Medicine. 2020;10(4):850-6.

59. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Annals of Internal Medicine. 2020;173(12):964-73.

60. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495.

61. Reiter P, Pennell M, Katz M. Acceptability of a COVID-19 Vaccine among Adults in the United States: How Many People Would Get Vaccinated? Vaccine. 2020;38.

62. Pogue K, Jensen JL, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, et al. Influences on Attitudes Regarding Potential COVID-19 Vaccination in the United States. Vaccines. 2020;8(4):E582.

63. Craig BM. United States COVID-19 Vaccination Preferences (CVP): 2020 Hindsight. The Patient. 2021;14(3):309-18.

64. Thunström L, Ashworth M, Finnoff D, Newbold SC. Hesitancy Toward a COVID-19 Vaccine. EcoHealth. 2021;18(1):44-60.

65. Rane MS, Kochhar S, Poehlein E, You W, Robertson MM, Zimba R, et al. Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study. American journal of epidemiology. 2022;191(4):570-83.

66. Kelly BJ, Southwell BG, McCormack LA, Bann CM, MacDonald PDM, Frasier AM, et al. Predictors of willingness to get a COVID-19 vaccine in the U.S. BMC Infectious Diseases. 2021;21(1):338.

67. Iacoella C, Ralli M, Maggiolini A, Arcangeli A, Ercoli L. Acceptance of COVID-19 vaccine among persons experiencing homelessness in the City of Rome, Italy. European review for medical and pharmacological sciences. 2021;25(7):3132-5.

68. Tucker JS, D'Amico EJ, Pedersen ER, Garvey R, Rodriguez A, Klein DJ. COVID-19 Vaccination Rates and Attitudes Among Young Adults With Recent Experiences of Homelessness. The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 2022;70(3):504-6.

69. Meehan AA, Yeh M, Gardner A, DeFoe TL, Garcia A, V, et al. COVID-19 Vaccine Acceptability Among Clients and Staff of Homeless Shelters in Detroit, Michigan, February 2021. Health promotion practice. 2022;23(1):35-41.

70. Rogers JH, Cox SN, Hughes JP, Link AC, Chow EJ, Fosse I, et al. Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington. Vaccine. 2022;40(1):122-32.

71. Dietze PM, Hall C, Price O, Stewart AC, Crawford S, Peacock A, Maher L. COVID-19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout. Drug and alcohol review. 2022;41(2):484-7.

72. Sullivan MC, Mistler C, Copenhaver MM, Wickersham JA, Ni Z, Kim RS, Shrestha R. Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2022;41(2):115-20.

73. Abramovich A, Pang N, Kunasekaran S, Moss A, A, Kiran T, Pinto AD. Examining COVID-19 vaccine uptake and attitudes among 2SLGBTQ+ youth experiencing homelessness. BMC public health. 2022;22(1):122.

74. Christodoulou J, Fehrenbacher AE, Shaw EH, Vincent EM, Saleska JL. COVID-19 prevention behaviors, trust, and intent to vaccinate among youth at risk for HIV. PloS one. 2022;17(3):e0266321.

75. Stern MF, Piasecki AM, Strick LB, Rajeshwar P, Tyagi E, Dolovich S, et al. Willingness to Receive a COVID-19 Vaccination Among Incarcerated or Detained Persons in Correctional and Detention Facilities - Four States, September-December 2020. MMWR Morbidity and mortality weekly report. 2021;70(13):473-7.

76. Shaw J, Anderson KB, Fabi RE, Thompson CA, Harris M, Aljabbarin N, et al. COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population. Vaccine. 2022;40(9):1231-7.

77. Crozier J, Christensen N, Li P, Stanley G, Clark DS, Selleck C. Rural, Underserved, and Minority Populations' Perceptions of COVID-19 Information, Testing, and Vaccination: Report from a Southern State. Population health management. 2022;25(3):413-22.

78. Scott VP, Hiller-Venegas S, Edra K, Prickitt J, Esquivel Y, Melendrez B, Rhee KE. Factors associated with COVID-19 vaccine intent among Latino SNAP participants in Southern California. BMC public health. 2022;22(1):653.

79. Morillon GF, Poder TG. Which factors drive the choice of the French-speaking Quebec population towards a COVID-19 vaccination programme: A discrete-choice experiment. Health Expect. 2024;27(1).

80. Cahill SR. Still in the Dark Regarding the Public Health Impact of COVID-19 on Sexual and Gender Minorities. American Journal of Public Health. 2021;111(9):1606-9.

81. Martin CA, Marshall C, Patel P, Goss C, Jenkins DR, Ellwood C, et al. SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study. PLoS medicine. 2021;18(11):e1003823.

82. Curtis HJ, Inglesby P, Morton CE, MacKenna B, Green A, Hulme W, et al. Trends and clinical characteristics of COVID-19 vaccine recipients: a federated analysis of 57.9 million patients' primary care records in situ using OpenSAFELY. The British journal of general practice : the journal of the Royal College of General Practitioners. 2022;72(714):e51-e62.

83. Hussain B, Latif A, Timmons S, Nkhoma K, Nellums LB. Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies. Vaccine. 2022;40(25):3413-32.

84. Peters MDJ. Addressing vaccine hesitancy and resistance for COVID-19 vaccines. International journal of nursing studies. 2022;131:104241.

85. Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Medical Research Methodology. 2022;22(1):287.

Table 1. General characteristics of included studies.

Author	Country	Study design	Date of data collection	Population	Sample size	Female sex proportion	Mean age	Vaccine acceptance	Hesitancy	Refusal	Unwillingness
Attwell(22)	Australia	Cross-sectional survey	29-May-20	General population	1316	60	58	65%	27%	8%	35%
Seale	Australia	Cross-sectional survey	24-Mar-20	General population	1420	52		80%	14%	6%	20%
Dietze	Australia	Cross-sectional survey	22-Dec-20	People who inject drugs at least monthly in the past 6 months	100	41	39	48%	37%	15%	52%
Enticott	Australia	Cross-sectional survey	7-Mar-21	General population	1166	49	51.7	78%	15%	7%	22%
Schernhammer	Austria	Cross-sectional survey	3-Dec-20	General population	1007	44	42	36%	23%	41%	64%
Kessels	Belgium	Cross-sectional survey	16-Oct-20	General population	2060			34%	57%	9%	66%
Lavoie	Canada	Cross-sectional survey	29-Mar-21	General population	15019	50	48	58%	0%	0%	42%
Basta	Canada	Cross-sectional survey	29-Dec-20	General population	23819	53		84%	12%	4%	16%
Abramovich	Canada	Cross-sectional survey	30-Jan-21	2SLGBTQ+ youth experiencing homelessness	139	61	20	64%	0%	0%	36%

Manca	Canada	Cross-sectional survey	10-Dec-20	Indigenous population	342	53		64%	17%	18%	35%
Bagic	Croatia	Cross-sectional survey	11-Apr-21	General population	765	52.4	49	64%	19%	17%	35%
Neumann-Böhme	Denmark	Cross-sectional survey	15-Apr-20	General population	7664			80%	12%	8%	20%
Detoc	France	Cross-sectional survey	20-Apr-20	General population	3656	89	67	78%	48%	0%	48%
Ward	France	Cross-sectional survey	4-May-20	General population	5018			76%	16%	8%	24%
Montagni	France	Cross-sectional survey	10-May-20	General population	1640	78.4		71%	11%	19%	30%
Ousseine	France	Cross-sectional survey	11-Apr-21	Men who have sex with men	18474	0	34	61%	22%	18%	40%
Coulaud	France	Cross-sectional survey	23-Dec-20	General population	3204	38.		60%	30%	10%	40%
Heyerdahl	France	Cross-sectional survey	16-Dec-20	General population	10000			57%	19%	24%	43%
Bendau	Germany	Cross-sectional survey	11-Jan-21	General population	1779	77.6	41	65%	24%	11%	35%

Kourlaba	Greece	Cross-sectional survey	3-May-20	General population	1004	51	41	58%	16%	26%	42%
Murphy	Ireland	Cross-sectional survey	5-Apr-20	General population	1041	51.5		65%	26%	9%	35%
Maor	Israel	Cross-sectional survey	6-Sep-20	General population	2024	52		76%	0%	24%	24%
Caserotti	Italy	Survey with repeated measures	30-Jun-20	General population	839	70.2	38	79%	0%	21%	21%
La Vecchia	Italy	Cross-sectional survey	28-Sep-20	General population	1055	51.7		54%	0%	46%	46%
Di Giuseppe	Italy	Cross-sectional survey	28-Apr-21	Incarcerated	685	0	42.4	64%	0%	36%	36%
Moscardino	Italy	Cross-sectional survey	28-Jun-21	General population	1200	49.2	29.8	73%	18%	8%	25%
Palamenghi	Italy	Cross-sectional survey		General population	968			59%	0%	41%	41%
Iacoella	Italy	Cross-sectional survey	15-Feb-21	persons experiencing homelessness	112	24.1	53.1	63%	4%	32%	36%
Yoda	Japan	Cross-sectional survey	30-Sep-20	General population	1100	46.9	44.8	66%	22%	12%	34%
Ihshimaru	Japan	Cross-sectional survey	26-Dec-20	General population	27036	48.9		38%	0%	63%	63%

Machida	Japan	Cross-sectional survey	18-Jan-21	General population	2956	50.6		62%	0%	38%	38%
Kadoya	Japan	Cross-sectional survey	25-Feb-21	General population	4253	35	50.3	47%	31%	22%	53%
Sekizawa	Japan	Cross-sectional survey	6-May-21	General population	11846	49.6	54	62%	30%	9%	38%
Soares	Portugal	Cross-sectional survey	8-Jan-21	General population	1943	67.7	47.7	35%	56%	9%	65%
Khaled	Qatar	Cross-sectional survey	25-Jan-21	General population	1912	31.7		43%	45%	12%	57%
Page	Switzerland	Cross-sectional survey	31-May-21	Undocumented migrants	812	60.9	39	41%	0%	59%	59%
Freeman	UK	Cross-sectional survey	11-May-20	General population	2501	51.4	46.6	48%	7%	5%	12%
Sethi	UK	Cross-sectional survey	9-Oct-20	General population	4884	69.9		79%	14%	7%	21%
Freeman	UK	Cross-sectional survey	17-Oct-20	General population	5114	49.2	46.9	72%	17%	12%	28%
Batty	UK	Cross-sectional survey	31-Dec-20	General population	11955	56.4		85%	15%	0%	15%

Chaudhuri	UK	Cross-sectional survey	31-Jan-21	General population	22421	58.5	55.4	89%	0%	11%	11%
Sherman	UK	Cross-sectional survey	17-Jul-20	General population	1494	51	46	64%	27%	9%	36%
Sherman	UK	Cross-sectional survey	15-Jan-21	General population	1500	51	45.6	74%	14%	9%	23%
Earnshaw	USA	Cross-sectional survey	14-Apr-20	General population	845	40.9	40	86%	0%	0%	14%
Fisher	USA	Cross-sectional survey	20-Apr-20	General population	991	51.5	18	58%	32%	11%	42%
Malik	USA	Cross-sectional survey	1-May-20	General population	672	57		67%	0%	0%	33%
Reiter	USA	Cross-sectional survey	31-May-20	General population	2006	56		48%	43%	9%	52%
Pogue	USA	Cross-sectional survey		General population	316	49.4		68%	23%	9%	32%
Craig	USA	Discrete choice experiment survey	11-Nov-20	General population	1153	52.3		61%	0%	17%	17%
Kelly	USA	Cross-sectional survey	30-Apr-20	General population	2279	52		75%	0%	25%	25%

Christodoulou	USA	Cross-sectional survey	30-Apr-20	Youth aged 18–28 at-risk for HIV	83	16	23	65%	0%	35%	35%
Sullivan	USA	Cross-sectional survey	01-May-20	People with opioid use disorder	234	56	46.8	32%	48%	20%	68%
Stern	USA	Cross-sectional survey	12-Dec-20	Incarcerated or detained persons	5110	17.6		45%	10%	45%	55%
Rogers	USA	Cross-sectional survey	28-Feb-21	Adult homeless shelter residents and staff	969	27.4	41	54%	18%	28%	46%
Crozier	USA	Cross-sectional survey	31-Dec-20	Rural, Underserved and Minority Populations in Alabama	3721	56.5		39%	27%	24%	51%
Thunström	USA	Cross-sectional survey	31-Mar-20	General population	3133	52	46	80%	0%	20%	20%
Rane	USA	Survey with repeated measures	01-Oct-20	General population	4571	53		85%	9%	6%	15%
Scott	USA	Cross-sectional survey	31-Jul-20	Latino SNAP participants (food programme)	486	93	40	48%	39%	13%	52%
Bogart	USA	Cross-sectional survey	31-Dec-20	Black Americans	207	71	50.8	30%	38%	32%	70%
Rosen	USA	Cross-sectional survey	31-May-21	Unhoused People in Los Angeles County	4949			74%	7%	17%	25%

Tucker	USA	Cross-sectional survey	1-Mar-21	Young adults with recent experiences of homelessness	134	32		50%	0%	50%	50%
Shaw	USA	Cross-sectional survey	1-Mar-21	Refugees	244	55.3	38.5	57%	18%	25%	43%
Nguyen	USA	Cross-sectional survey	2-Aug-20	General population	63266	50.6		86%	5%	9%	14%
Meehan	USA	Cross-sectional survey	23-Feb-21	Clients and staff of homeless shelters	106		44	58%	11%	31%	42%



Title :Figure 1. Random-effects meta-analysis of COVID-19 vaccine acceptance in the general population. Caption: For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

85x135mm (300 x 300 DPI)



Title : Figure 2. Random-effects meta-analysis of COVID-19 vaccine acceptance in special populations
Caption: For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

82x55mm (300 x 300 DPI)

Table of contents for the supplementary material

Supplementary material

1. Supplementary section 1: methods

a. Search strategy (concepts / block building approach)

Overview databases and results

Date last searched: 30.11.2022

PubMed

1 (((Coronaviridae[MeSH Terms] OR Coronavirus Infections[MeSH Terms] OR 2019 novel coronavirus disease[Title/Abstract] OR covid-19[Title/Abstract] OR sars-cov-2 infection[Title/Abstract] OR sars coronavirus[Title/Abstract] OR 2019 novel coronavirus infection[Title/Abstract] OR 2019-ncov infection[Title/Abstract] OR 2019-ncov disease[Title/Abstract]) AND (Vaccines[MeSH Terms] OR Immunization[MeSH Terms] OR vaccines[Title/Abstract]) AND (patient acceptance of health care[Title/Abstract] OR vaccination[Title/Abstract] OR attitude[Title/Abstract] OR willingness[Title/Abstract] OR readiness[Title/Abstract] OR preparedness[Title/Abstract] OR disposition[Title/Abstract] OR acceptance[Title/Abstract] OR acceptability[Title/Abstract] OR perception[Title/Abstract] OR receptivity[Title/Abstract] OR hesitancy[Title/Abstract] OR intention[Title/Abstract] OR attitudes[Title/Abstract])) AND ((Adult[MeSH Terms] OR Young Adult[MeSH Terms] OR Middle Aged[MeSH Terms] OR Aged[MeSH Terms] OR Aged, 80 and over[MeSH Terms]))) NOT (editorial/ or letter/ or case reports/ or comments/) Filters: Humans, Exclude preprints, from 2006 – 2022 (2600)

Embase

#	Concept	Search String	Results
1	COVID-19	'coronaviridae'/exp OR 'coronavirus infections' OR '2019 novel coronavirus disease':ti,ab OR 'covid-19':ti,ab OR 'sars-cov-2 infection':ti,ab OR 'sars coronavirus':ti,ab OR '2019 novel coronavirus infection':ti,ab OR '2019-ncov infection':ti,ab OR '2019-ncov disease':ti,ab	171,270
2	Vaccine acceptance	('patient acceptance of health care':ti,ab OR 'vaccination':ti,ab OR 'attitude':ti,ab OR willingness:ti,ab OR readiness:ti,ab OR preparedness:ti,ab OR disposition:ti,ab OR acceptance:ti,ab OR acceptability:ti,ab OR perception:ti,ab OR receptivity:ti,ab OR hesitancy:ti,ab OR intention:ti,ab OR attitudes:ti,ab)	376,320
3	COVID vaccine	'vaccines'/exp OR 'immunization'/exp OR vaccin*:ti,ab OR immun*:ti,ab OR 'vaccines':ti,ab OR (('covid-19 vaccin*' NEAR/3 'covid-19'):ti,ab)	1,385,897
4	Combine	#1 AND #2 AND #3	18,915
5	Filters	#4 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'tombstone'/it)	10135
6	Population	([adult]/lim OR [young adult]/lim OR [middle aged]/lim OR [aged]/lim OR [very elderly]/lim)	3,660,406
7	Filters	'animal cell'/de OR 'animal experiment'/de OR 'animal model'/de OR 'animal tissue'/de OR 'case report'/de OR 'nonhuman'/de	2,971,939
8	Combine	(#5 AND #6) NOT #7	2,274

Dimensions ai

ID Search Hits

Vaccine acceptance covid free text in title and abstract (1172)

Google Scholar

"covid" "vaccine acceptance" -program: first 200

b. Figure S1 Flow diagram for selection of studies

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only.



*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

c. List of excluded references after full-text screening

Exclusion reason	Reference
Wrong population (n=103)	1-103
Convenience sample (n=23)	104-126
Outcomes missing (n=21)	127-147
Qualitative study (n=3)	148-150
Focusing on booster vaccine (n=2)	151-152

1. Galanis, P. *et al.* Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: A systematic review and meta-analysis. *Preventive medicine* 157, 106994 (2022)
2. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States - ScienceDirect. (2022).
3. Luo, H. *et al.* Willingness to Get a COVID-19 Vaccine and Reasons for Hesitancy Among Medicare Beneficiaries: Results From a National Survey. *Journal of public health management and practice : JPHMP* 28, 70–76 (2022).
4. Serrazina, F., Sobral Pinho, A., Cabral, G., Salavisa, M. & Correia, A. S. Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients. *Mult Scler Relat Disord* 51, 102880 (2021).
5. Unroe, K., Evans, R., Weaver, L., Rusyniak, D. & Blackburn, J. Willingness of Long-Term Care Staff to Receive a COVID -19 Vaccine: A Single State Survey. *Journal of the American Geriatrics Society* 69, (2020).
6. Wagner, E. F. *et al.* Virtual town halls addressing vaccine hesitancy among racial/ethnic minorities: Preliminary findings. *Journal of the American Pharmacists Association : JAPhA* 62, 317–325 (2022).
7. Vaccines | Free Full-Text | Intention to Be Vaccinated for COVID-19 among Italian Nurses during the Pandemic. (2022).
8. Vaccines | Free Full-Text | Attitudes towards COVID-19 Vaccination among Hospital Staff—Understanding What Matters to Hesitant People. (2022).
9. 'Vaccine hesitancy' among university students in Italy during the COVID-19 pandemic | SpringerLink. (2022).
10. Lo Moro, G., Cugudda, E., Bert, F., Raco, I. & Siliquini, R. Vaccine Hesitancy and Fear of COVID-19 Among Italian Medical Students: A Cross-Sectional Study. *Journal of community health* 47, 475–483 (2022).
11. Kelkar, A. H. *et al.* Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar. *Healthcare (Basel)* 9, 351 (2021).
12. Riad, A. *et al.* Universal Predictors of Dental Students' Attitudes towards COVID-19 Vaccination: Machine Learning-Based Approach. *Vaccines (Basel)* 9, 1158 (2021).
13. Lennon, R. P. *et al.* Unique Predictors of Intended Uptake of a COVID-19 Vaccine in Adults Living in a Rural College Town in the United States. *American journal of health promotion : AJHP* 36, 180–184 (2022).
14. Euser, S., Kroese, F. M., Derks, M. & de Bruin, M. Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands. *Vaccine* 40, 833–836 (2022).
15. Trent, M., Seale, H., Chughtai, A. A., Salmon, D. & MacIntyre, C. R. Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the United States, United Kingdom, and Australia. *Vaccine* 40, 2498–2505 (2022).

16. Hosokawa, Y. *et al.* The Prevalence of COVID-19 Vaccination and Vaccine Hesitancy in Pregnant Women: An Internet-based Cross-sectional Study in Japan. *Journal of epidemiology* 32, 188–194 (2022).
17. Grüner, S. & Krüger, F. The intention to be vaccinated against COVID-19: stated preferences before vaccines were available. *Applied Economics Letters* 28, 1847–1851 (2021).
18. Kavanagh, A., Dickinson, H., Dimov, S., Shields, M. & McAllister, A. The COVID-19 vaccine intentions of Australian disability support workers. *Australian and New Zealand journal of public health* 46, 314–321 (2022).
19. Harsch, I. A., Ortloff, A., Reinhöfer, M. & Epstude, J. Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers. *GMS Hyg Infect Control* 16, Doc15 (2021).
20. G, D. G. *et al.* Surveying willingness toward SARS-CoV-2 vaccination of healthcare workers in Italy. *Expert review of vaccines* 20, (2021).
21. Chapman, G. *et al.* 'Scary to get, more scary not to': COVID-19 vaccine acceptance among healthcare workers in Central Queensland, Australia, a cross-sectional survey. *Communicable diseases intelligence (2018)* 46, (2022).
22. Stuckelberger, S. *et al.* SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland. *Viruses* 13, 1199 (2021).
23. Jaiswal, J. *et al.* SARS-CoV-2 Vaccination Hesitancy and Behaviors in a National Sample of People Living with HIV. *AIDS patient care and STDs* 36, 34–44 (2022).
24. Temsah, M.-H. *et al.* SARS-CoV-2 B.1.1.7 UK Variant of Concern Lineage-Related Perceptions, COVID-19 Vaccine Acceptance and Travel Worry Among Healthcare Workers. *Front Public Health* 9, 686958 (2021).
25. Grafova, I. B. *et al.* Racial and ethnic differences in vaccine hesitancy Among registered nurses in New Jersey: A cross-sectional survey. *American journal of infection control* 50, 572–574 (2022).
26. Niznik, J. D. *et al.* Perceptions of COVID-19 vaccines among healthcare assistants: A national survey. *Journal of the American Geriatrics Society* 70, 8–18 (2022).
27. Hogan, C. M. *et al.* Perceptions of COVID-19 Vaccine Incentives Among Adolescents and Young Adults. *JAMA network open* 5, e2216628 (2022).
28. Alhazza, S. F. *et al.* Parents' Hesitancy to Vaccinate Their Children Against COVID-19, a Country-Wide Survey. *Frontiers in public health* 10, 755073 (2022).
29. Bell, S., Clarke, R., Mounier-Jack, S., Walker, J. L. & Paterson, P. Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. *Vaccine* 38, 7789–7798 (2020).
30. Bianco, A. *et al.* Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy. *Expert review of vaccines* 21, 541–547 (2022).
31. Choi, K., Becerra-Culqui, T., Bhakta, B., Bruxvoort, K. & Coleman, K. J. Parent intentions to vaccinate children with autism spectrum disorder against COVID-19. *Journal of pediatric nursing* 63, 108–110 (2022).
32. Afifi, T. O. *et al.* Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies. *Vaccine* 3473–3479 (2021).
33. Pierantoni, L. *et al.* Nationwide COVID-19 survey of Italian parents reveals useful information on attitudes to school attendance, medical support, vaccines and drug trials. *Acta Paediatr* 10.1111/apa.15614 (2020) doi:10.1111/apa.15614.
34. Brandt, E. J. *et al.* National Study of Youth Opinions on Vaccination for COVID-19 in the U.S. *J Adolesc Health* 68, 869–872 (2021).
35. Szmyd, B. *et al.* Medical Students and SARS-CoV-2 Vaccination: Attitude and Behaviors. *Vaccines (Basel)* 9, 128 (2021).
36. Halbrook, M. *et al.* Longitudinal Assessment of Coronavirus Disease 2019 Vaccine Acceptance and Uptake Among Frontline Medical Workers in Los Angeles, California. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 74, 1166–1173 (2022).

37. Ciardi, F. *et al.* Knowledge, Attitudes and Perceptions of COVID-19 Vaccination among Healthcare Workers of an Inner-City Hospital in New York. *Vaccines (Basel)* 9, 516 (2021).
38. Elhadi, M. *et al.* Knowledge, attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine: a cross-sectional study. *BMC Public Health* 21, 955 (2021).
39. Kreuter, M. W. *et al.* Intention to vaccinate children for COVID-19: A segmentation analysis among Medicaid parents in Florida. *Preventive medicine* 156, 106959 (2022).
40. Kaida, A. *et al.* Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada. *AIDS and behavior* 26, 2242–2255 (2022).
41. Gagneux-Brunon, A. *et al.* Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey. *Journal of Hospital Infection* 108, 168–173 (2021).
42. Talarek, E., Warzecha, J., Banasiuk, M. & Banaszkiewicz, A. Influenza Vaccination Coverage and Intention to Receive Hypothetical Ebola and COVID-19 Vaccines among Medical Students. *Vaccines (Basel)* 9, 709 (2021).
43. Caron, B., Neuville, E. & Peyrin-Biroulet, L. Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey. *Digestive diseases and sciences* 67, 2067–2073 (2022).
44. Impact of the COVID-19 pandemic on ophthalmic specialist training in Poland. | PLoS One;16(9): e0257876, 2021. | MEDLINE. (2022).
45. Janssen, C. *et al.* Hesitancy towards COVID-19 Vaccination among Healthcare Workers: A Multi-Centric Survey in France. *Vaccines* 9, 547 (2021).
46. Baghdadi, L. R., Alghaihb, S. G., Abuhaimed, A. A., Alkelabi, D. M. & Alqahtani, R. S. Healthcare Workers' Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study. *Vaccines (Basel)* 9, 465 (2021).
47. Patil, U. *et al.* Health Literacy, Digital Health Literacy, and COVID-19 Pandemic Attitudes and Behaviors in U.S. College Students: Implications for Interventions. *International Journal of Environmental Research and Public Health* 18, 3301 (2021).
48. Thompson, H. S. *et al.* Factors Associated With Racial/Ethnic Group–Based Medical Mistrust and Perspectives on COVID-19 Vaccine Trial Participation and Vaccine Uptake in the US. *JAMA Netw Open* 4, e2111629 (2021).
49. Goldman, R. D. *et al.* Factors associated with parents' willingness to enroll their children in trials for COVID-19 vaccination. *Hum Vaccin Immunother* 17, 1607–1611 (2022).
50. Letterie, M. C. *et al.* Factors Associated With Parental COVID-19 Vaccination Acceptance. *Clinical pediatrics* 61, 393–401 (2022).
51. Puteikis, K. & Mameniškienė, R. Factors Associated with COVID-19 Vaccine Hesitancy among People with Epilepsy in Lithuania. *Int J Environ Res Public Health* 18, 4374 (2021).
52. Daniel, C. L., Williams, J., Legg, R., McGowen, C. & Stutzman, J. Factors associated with COVID-19 vaccination intentions among adults in the deep South. *Vaccine* 40, 841–853 (2022).
53. Skeens, M. A. *et al.* Factors affecting COVID-19 vaccine hesitancy in parents of children with cancer. *Pediatric blood & cancer* 69, e29707 (2022).
54. Di Giuseppe, G., Pelullo, C. P., Della Polla, G., Pavia, M. & Angelillo, I. F. Exploring the Willingness to Accept SARS-CoV-2 Vaccine in a University Population in Southern Italy, September to November 2020. *Vaccines (Basel)* 9, 275 (2021).
55. Purnell, M. *et al.* Exploring COVID-19 vaccine hesitancy at a rural historically black college and university. *Journal of the American Pharmacists Association : JAPhA* 62, 340–344 (2022).
56. Hahn, M. B., Fried, R. L., Cochran, P. & Eichelberger, L. P. Evolving perceptions of COVID-19 vaccines among remote Alaskan communities. *International journal of circumpolar health* 81, 2021684 (2022).
57. Gravelle, T. B., Phillips, J. B., Reifler, J. & Scotto, T. J. Estimating the size of 'anti-vax' and vaccine hesitant populations in the US, UK, and Canada: comparative latent class modeling of vaccine attitudes. *Human vaccines & immunotherapeutics* 18, 2008214 (2022).

58. Enhancing COVID-19 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy - PubMed. (2022).
59. Maltezou, H. C. *et al.* Determinants of intention to get vaccinated against COVID-19 among healthcare personnel in hospitals in Greece. *Infect Dis Health* 26, 189–197 (2021).
60. Gray, A. & Fisher, C. B. Determinants of COVID-19 Vaccine Uptake in Adolescents 12-17 Years Old: Examining Pediatric Vaccine Hesitancy Among Racially Diverse Parents in the United States. *Frontiers in public health* 10, 844310 (2022).
61. Costantino, A. *et al.* COVID-19 Vaccine: A Survey of Hesitancy in Patients with Celiac Disease. *Vaccines* 9, 511 (2021).
62. Jefsen, O. H. *et al.* COVID-19 vaccine willingness amongst patients with mental illness compared with the general population. *Acta Neuropsychiatrica* 33, 273–276 (2021).
63. Chudasama, R. V. *et al.* COVID-19 vaccine uptake and hesitancy opinions from frontline health care and social care workers: Survey data from 37 countries. *Diabetes & metabolic syndrome* 16, 102361 (2022).
64. Doyle-Campbell, C., Mattison, M. J., Amedeo, V., Gaffney, S. & Achadinha, H. COVID-19 vaccine status and hesitancy in pharmacy students. *Currents in pharmacy teaching & learning* 14, 476–481 (2022).
65. Iadarola, S., Siegel, J. F., Gao, Q., McGrath, K. & Bonuck, K. A. COVID-19 vaccine perceptions in New York State's intellectual and developmental disabilities community. *Disability and health journal* 15, 101178 (2022).
66. Lutrick, K. *et al.* COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers. *Vaccine* 40, 494–502 (2022).
67. Watts, A. W. *et al.* COVID-19 Vaccine Intentions and Perceptions Among Public School Staff of the Greater Vancouver Metropolitan Area, British Columbia, Canada. *Frontiers in public health* 10, 832444 (2022).
68. Gurenlian, J. R. *et al.* COVID-19 Vaccine Intention and Hesitancy of Dental Hygienists in the United States. *Journal of dental hygiene : JDH* 96, 5–16 (2022).
69. Wu, H., Ward, M., Brown, A., Blackwell, E. & Umer, A. COVID-19 Vaccine intent in appalachian patients with multiple sclerosis. *Multiple sclerosis and related disorders* 57, 103450 (2022).
70. Sieber, W. J. *et al.* COVID-19 vaccine hesitancy: Associations with gender, race, and source of health information. *Families, systems & health : the journal of collaborative family healthcare* 40, 252–261 (2022).
71. Fedele, F. *et al.* COVID-19 vaccine hesitancy: a survey in a population highly compliant to common vaccinations. *Human Vaccines & Immunotherapeutics* 17, 3348–3354 (2021).
72. Uhr, L. & Mateen, F. J. COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey. *Multiple sclerosis (Houndmills, Basingstoke, England)* 28, 1072–1080 (2022).
73. Al-Mulla, R., Abu-Madi, M., Talafha, Q. M., Tayyem, R. F. & Abdallah, A. M. COVID-19 Vaccine Hesitancy in a Representative Education Sector Population in Qatar. *Vaccines* 9, 665 (2021).
74. Yang, Y., Dobalian, A. & Ward, K. D. COVID-19 Vaccine Hesitancy and Its Determinants Among Adults with a History of Tobacco or Marijuana Use. *J Community Health* 46, 1090–1098 (2021).
75. Tsai, R. *et al.* COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey. *JMIR public health and surveillance* 8, e29872 (2022).
76. Hubach, R. *et al.* COVID-19 vaccine hesitancy among rural Oklahomans. *Rural and remote health* 22, 7128 (2022).
77. Lucia, V. C., Kelekar, A. & Afonso, N. M. COVID-19 vaccine hesitancy among medical students. *J Public Health (Oxf)* fdaa230 (2020) doi:10.1093/pubmed/fdaa230.
78. Teasdale, C. A. *et al.* COVID-19 Vaccine Coverage and Hesitancy Among New York City Parents of Children Aged 5-11 Years. *American journal of public health* 112, 931–936 (2022).

79. Morris, J. L., Baniak, L. M., Luyster, F. S. & Dunbar-Jacob, J. Covid-19 vaccine confidence and hesitancy in nursing students and faculty at a large academic medical center. *Nursing outlook* 70, 347–354 (2022).
80. Dzieciolowska, S. *et al.* Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: A multicenter survey. *Am J Infect Control* 49, 1152–1157 (2021).
81. Kelekar, A. K., Lucia, V. C., Afonso, N. M. & Mascarenhas, A. K. COVID-19 vaccine acceptance and hesitancy among dental and medical students. *The Journal of the American Dental Association* 152, 596–603 (2021).
82. Shaaban, R. *et al.* COVID-19 Vaccine Acceptance among Social Media Users: A Content Analysis, Multi-Continent Study. *International journal of environmental research and public health* 19, (2022).
83. COVID-19 Vaccine Acceptance Among Health Care Workers in the United States | medRxiv. (2022).
84. Kozak, A. & Nienhaus, A. COVID-19 Vaccination: Status and Willingness to Be Vaccinated among Employees in Health and Welfare Care in Germany. *Int J Environ Res Public Health* 18, 6688 (2021).
85. Xiang, X. M. *et al.* COVID-19 vaccination willingness among people with multiple sclerosis. *Mult Scler J Exp Transl Clin* 7, 20552173211017160 (2021).
86. Fulda, E. S. *et al.* COVID-19 Vaccination Rates in a Global HIV Cohort. *The Journal of infectious diseases* 225, 603–607 (2022).
87. Myers, A., Ipsen, C. & Lissau, A. COVID-19 vaccination hesitancy among Americans with disabilities aged 18-65: An exploratory analysis. *Disability and health journal* 15, 101223 (2022).
88. Kecojevic, A., Basch, C. H., Sullivan, M., Chen, Y.-T. & Davi, N. K. COVID-19 Vaccination and Intention to Vaccinate Among a Sample of College Students in New Jersey. *J Community Health* 46, 1059–1068 (2021).
89. Haile, Z. T., Ruhil, A., Bates, B. R., Hall, O. & Grijalva, M. J. Correlates of Covid-19 Vaccine Acceptance among Residents of Ohio: A Cross-sectional Study. *BMC public health* 22, 226 (2022).
90. Goldman, R. D. *et al.* Caregivers' Willingness to Accept Expedited Vaccine Research During the COVID-19 Pandemic: A Cross-sectional Survey. *Clin Ther* 42, 2124–2133 (2020).
91. Heyne, S., Esser, P., Werner, A., Lehmann-Laue, A. & Mehnert-Theuerkauf, A. Attitudes toward a COVID-19 vaccine and vaccination status in cancer patients: a cross-sectional survey. *Journal of cancer research and clinical oncology* 148, 1363–1374 (2022).
92. Attitudes of Patients with Cancer towards Vaccinations—Results of Online Survey with Special Focus on the Vaccination against COVID-19 - PMC. (2022).
93. Verger, P. *et al.* Attitudes of healthcare workers towards COVID-19 vaccination: a survey in France and French-speaking parts of Belgium and Canada, 2020. *Euro Surveill* 26, (2021).
94. Szmyd, B. *et al.* Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland. *Vaccines (Basel)* 9, 218 (2021).
95. Eyllon, M. *et al.* Associations between psychiatric morbidity and COVID-19 vaccine hesitancy: An analysis of electronic health records and patient survey. *Psychiatry research* 307, 114329 (2022).
96. Bellis, M. A. *et al.* Associations between adverse childhood experiences, attitudes towards COVID-19 restrictions and vaccine hesitancy: a cross-sectional study. *BMJ open* 12, e053915 (2022).
97. Shaw, J. *et al.* Assessment of US Healthcare Personnel Attitudes Towards Coronavirus Disease 2019 (COVID-19) Vaccination in a Large University Healthcare System. *Clin Infect Dis* 73, 1776–1783 (2021).
98. Gardner, J. *et al.* An assessment of Veterans attitudes and willingness to receiving the COVID-19 vaccine: a mixed methods study. *BMC infectious diseases* 22, 308 (2022).
99. Temsah, M.-H. *et al.* Adenovirus and RNA-based COVID-19 vaccines' perceptions and acceptance among healthcare workers in Saudi Arabia: a national survey. *BMJ Open* 11, e048586 (2021).

100. de Sousa, M. J. *et al.* Acceptance of SARS-CoV-2 vaccination among cancer patients in Portugal: attitudes and associated factors. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 30, 4565–4570 (2022).
101. Nohl, A. *et al.* Acceptance of COVID-19 Vaccination among Front-Line Health Care Workers: A Nationwide Survey of Emergency Medical Services Personnel from Germany. *Vaccines (Basel)* 9, 424 (2021).
102. Pataka, A. *et al.* Acceptability of healthcare professionals to get vaccinated against COVID-19 two weeks before initiation of national vaccination in Greece. *European Respiratory Journal* 58, (2021).
103. Qattan, A. M. N. *et al.* Acceptability of a COVID-19 Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia. *Front Med (Lausanne)* 8, 644300 (2021).
104. Qunaibi, E. A. *et al.* A high rate of COVID-19 vaccine hesitancy in a large-scale survey on Arabs. *eLife* 10, e68038 (2021).
105. Latkin, C. *et al.* A longitudinal study of vaccine hesitancy attitudes and social influence as predictors of COVID-19 vaccine uptake in the US. *Human vaccines & immunotherapeutics* 18, 2043102 (2022).
106. Alqudeimat, Y. *et al.* Acceptance of a COVID-19 Vaccine and Its Related Determinants among the General Adult Population in Kuwait. *Med Princ Pract* 30, 262–271 (2021).
107. Babicki, M. & Mastalerz-Migas, A. Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland. *Vaccines (Basel)* 9, 503 (2021).
108. Gasteiger, N., Gasteiger, C., Vedhara, K. & Broadbent, E. Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach. *Vaccine* 40, 3461–3465 (2022).
109. Romer, D. & Jamieson, K. H. Conspiracy theories as barriers to controlling the spread of COVID-19 in the U.S. *Soc Sci Med* 263, 113356 (2020).
110. Brownstein, N. C. *et al.* COVID-19 vaccine behaviors and intentions among a national sample of United States adults ages 18-45. *Preventive medicine* 160, 107038 (2022).
111. Niankara, I. COVID-19 Vaccine Development in a Quadruple Helix Innovation System: Uncovering the Preferences of the Fourth Helix in the UAE. *Journal of Open Innovation: Technology, Market, and Complexity* 132–132 (2020).
112. Holeva, V., Parlapani, E., Nikopoulou, V. A., Nouskas, I. & Diakogiannis, I. COVID-19 vaccine hesitancy in a sample of Greek adults. *Psychology, health & medicine* 27, 113–119 (2022).
113. Waite, N. M., Pereira, J. A., Houle, S. K. D., Gilca, V. & Andrew, M. K. COVID-19's Impact on Willingness to Be Vaccinated against Influenza and COVID-19 during the 2020/2021 Season: Results from an Online Survey of Canadian Adults 50 Years and Older. *Vaccines (Basel)* 9, 346 (2021).
114. COVID-19 vaccine hesitancy and attitudes in Qatar: A national cross-sectional survey of a migrant-majority population - Alabdulla - 2021 - Influenza and Other Respiratory Viruses - Wiley Online Library. (2022).
115. Al-Mohaithef, M. & Padhi, B. K. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. *J Multidiscip Healthc* 13, 1657–1663 (2020).
116. Kreps, S. *et al.* Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. *JAMA Netw Open* 3, e2025594 (2020).
117. Dorman, C. *et al.* Factors Associated with Willingness to be Vaccinated Against COVID-19 in a Large Convenience Sample. *J Community Health* 46, 1013–1019 (2021).
118. Nikolovski, J. *et al.* Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. *PLoS One* 16, e0251963 (2021).
119. Sallam, M. *et al.* High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. *Vaccines (Basel)* 9, 42 (2021).

120. Biasio, L. R., Bonaccorsi, G., Lorini, C., Mazzini, D. & Pecorelli, S. Italian Adults' Likelihood of Getting COVID-19 Vaccine: A Second Online Survey. *Vaccines (Basel)* 9, 268 (2021).
121. Gutierrez, S., Logan, R., Marshall, C., Kerns, J. & Diamond-Smith, N. Predictors of COVID-19 Vaccination Likelihood Among Reproductive-Aged Women in the United States. *Public health reports (Washington, D.C. : 1974)* 137, 588–596 (2022).
122. Faasse, K. & Newby, J. Public Perceptions of COVID-19 in Australia: Perceived Risk, Knowledge, Health-Protective Behaviors, and Vaccine Intentions. *Front Psychol* 11, 551004 (2020).
123. Nguyen, L. H. *et al.* Self-reported COVID-19 vaccine hesitancy and uptake among participants from different racial and ethnic groups in the United States and United Kingdom. *Nature communications* 13, 636 (2022).
124. Sethi, S. *et al.* The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy. *BMJ Open* 11, e048856 (2021).
125. Abu-Farha, R. *et al.* Willingness of Middle Eastern public to receive COVID-19 vaccines. *Saudi Pharm J* 29, 734–739 (2021).
126. Willingness to Be Vaccinated against COVID-19 in Spain before the Start of Vaccination: A Cross-Sectional Study - PubMed. (2022).
127. García, L. Y. & Cerda, A. A. Contingent assessment of the COVID-19 vaccine. *Vaccine* 38, 5424–5429 (2020).
128. Freeman, D. *et al.* Coronavirus conspiracy beliefs, mistrust, and compliance with government guidelines in England. *Psychological medicine* 52, 251–263 (2022).
129. Fridman, A., Gershon, R. & Gneezy, A. COVID-19 and vaccine hesitancy: A longitudinal study. *PLoS One* 16, e0250123 (2021).
130. Knight, K. R. *et al.* COVID-19 Testing and Vaccine Acceptability Among Homeless-Experienced Adults: Qualitative Data from Two Samples. *Journal of general internal medicine* 37, 823–829 (2022).
131. Salali, G. D. & Uysal, M. S. COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. *Psychol Med* 1–3 (2022) doi:10.1017/S0033291720004067.
132. Levin, J. & Bradshaw, M. Determinants of COVID-19 skepticism and SARS-CoV-2 vaccine hesitancy: findings from a national population survey of U.S. adults. *BMC public health* 22, 1047 (2022).
133. Frontiers | A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2 | Psychology. (2022).
134. McCaffery, K. J. *et al.* Health literacy and disparities in COVID-19-related knowledge, attitudes, beliefs and behaviours in Australia. *Public Health Res Pract* 30, 30342012 (2020).
135. Borriello, A., Master, D., Pellegrini, A. & Rose, J. M. Preferences for a COVID-19 vaccine in Australia. *Vaccine* 39, 473–479 (2021).
136. Kreps, S., Dasgupta, N., Brownstein, J. S., Hswen, Y. & Kriner, D. L. Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation. *NPJ Vaccines* 6, 73 (2021).
137. Hursh, S. R., Strickland, J. C., Schwartz, L. P. & Reed, D. D. Quantifying the Impact of Public Perceptions on Vaccine Acceptance Using Behavioral Economics. *Front Public Health* 8, 608852 (2020).
138. Benis, A., Seidmann, A. & Ashkenazi, S. Reasons for Taking the COVID-19 Vaccine by US Social Media Users. *Vaccines (Basel)* 9, 315 (2021).
139. Callaghan, T., Lueck, J. A., Trujillo, K. L. & Ferdinand, A. O. Rural and Urban Differences in COVID-19 Prevention Behaviors. *The Journal of Rural Health* 37, 287–295 (2021).
140. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine. *Ugeskriftet.dk* (2022).

141. Ku, L. The Association of Social Factors and Health Insurance Coverage with COVID-19 Vaccinations and Hesitancy, July 2021. *Journal of general internal medicine* 37, 409–414 (2022).
142. Rzymski, P., Zeyland, J., Poniedziałek, B., Małecka, I. & Wysocki, J. The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland. *Vaccines (Basel)* 9, 382 (2021).
143. Felemban, R. M., Tashkandi, E. M. & Mohorjy, D. K. The willingness of the Saudi Arabian population to participate in the COVID-19 vaccine trial: A case-control study. *J Taibah Univ Med Sci* 16, 612–618 (2021).
144. Guidry, J. P. D. *et al.* U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic. *Vaccine* 39, 2452–2457 (2021).
145. Dror, A. A. *et al.* Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol* 35, 775–779 (2020).
146. Catma, S. & Varol, S. Willingness to Pay for a Hypothetical COVID-19 Vaccine in the United States: A Contingent Valuation Approach. *Vaccine* (2021) doi:10.3390/vaccines9040318.
147. Burch, A. E., Lee, E., Shackelford, P., Schmidt, P. & Bolin, P. Willingness to Vaccinate Against COVID-19: Predictors of Vaccine Uptake Among Adults in the US. *Journal of prevention (2022)* 43, 83–93 (2022).
148. McFadden, S. M. *et al.* Confidence and Hesitancy During the Early Roll-out of COVID-19 Vaccines Among Black, Hispanic, and Undocumented Immigrant Communities: a Review. *Journal of urban health : bulletin of the New York Academy of Medicine* 99, 3–14 (2022).
149. Butler, J. Z. *et al.* COVID-19 vaccination readiness among multiple racial and ethnic groups in the San Francisco Bay Area: A qualitative analysis. *PloS one* 17, e0266397 (2022).
150. Teixeira da Silva, D. *et al.* COVID-19 Vaccine Acceptance among an Online Sample of Sexual and Gender Minority Men and Transgender Women. *Vaccines (Basel)* 9, 204 (2021).
151. Sonderskov, K. M., Vistisen, H. T., Dinesen, P. T. & Ostergaard, S. D. A positive update on COVID-19 booster vaccine willingness among Danes. *Danish medical journal* 69, (2022).
152. Lennon, R. P. *et al.* Underserved population acceptance of combination influenza-COVID-19 booster vaccines. *Vaccine* 40, 562–567 (2022).

d. Definitions of variables and sources

For individual studies:

Items	Description
Study Identification	Authors, journal, and date of publication, doi
Study design	Quantitative, Qualitative, Other
Data Collection	Period of data collection
Geographic Context	Country, City/State, multi-country study
Sampling Method	Survey, Interviews, Other
Study size	Number of participants
Study population	General Population or marginalized, mean age, gender ratio, other characteristics if reported
Vaccine acceptability	Percentage of population accepting, being hesitant about, or refusing a Covid-19 vaccine
Promoters	Reasons for accepting a vaccine
Barriers	Reasons for refusing a vaccine
Demographic characteristics	Vaccine acceptance, hesitancy and refusal across demographic characteristics, as reported

Per country :

Data Sources : OECD, The World Bank, National Public Health Offices, Ourworldindata.org, US National Center for Education Statistics, Eurostat Database, Pew Research Center

Currency is current US dollars

Items	Description
Vaccination Data	
Vaccine approval	Date of first vaccine approval
Vaccination rates, past	Double, single and total vaccination rates as of 26.11.2021
General Demographic Data	
Population	Total population and percentage of foreign-born population
Gender ratio	Percentage of male population
Population, old	Population ages 65 and above, total
Life expectancy	Life expectancy at birth, total years
Religion and Ethnicity	
Religion and Ethnicity	Undenominational, Christians, Muslims, Hindus, Jews, Folk Religions, Buddhists, Others. Pew Research Center
Education	
Educational attainment	Educational attainment, primary to Doctoral or equivalent, population 25+ years. OECD
School enrollment	School enrollment, primary, % gross. OECD
Economical Indicators	
GDP	GDP per capita. OECD

Poverty Gap	Of total population. OECD
Poverty Rate	Of total population. OECD
Gender wage gap	Of total population. OECD
Unemployement Rate	Of total population. OECD
Gini Coefficient	OECD
Social Protection	
Social Spending	Cash-benefits, direct in-kind provision of goodds and services, and tax breaks with social purposes. OECD
Sociopolitical indicators of inequality	
Violence Against Women	Prevalence in the lifetime. OECD
Social Institutions and Gender	Discrimination in the family, Restricted access to resources and assets, restricted physical integrity, Restricted civil liberties. OECD, Index
Perceived Health	Of total population. OECD
People at Risk of Poverty or Social Exclusion	Index, Eurostat
Long Hours in Paid Work	Of total population. OECD
Well-Being	
Housing Overcrowding	Of total population. OECD
Social Connections	Social support and satisfaction with personal relationships, OECD
Housing Cost Overburden	Of total population. OECD
Subjective Well-Being	Of total population. OECD
Difficulty making ends meet	Of total population. OECD
Negative affect balance	Of total population. OECD
Work-life balance	Of total population. OECD
Quality of healthcare	
Universal healthcare	Yes/No
Health spendings	As share of GDP. The World Bank
Health coverage	Of total population. OECD
Consultations skipped due to cost	Per 100 patients. OECD
Medical Tests, treatment or follow-up skipped due to costs	Per 100 patients. OECD
Prescribed medicines skipped due to costs	Per 100 patients. OECD
Covid policy measures and downsides of not getting vaccine	
COVID-19 Stringency Index	Oxford Coronavirus Government Response Tracker (OxCGRT), Index

2. Supplementary section 2: Assessment of quality and risk of bias results

Table S1. Risk of bias assessment of included studies (Adapted from Hoy et al)

Author	Was the study´s target population representative?	Was the sample frame a close representation of the target population?	Was the sample randomly selected?	Was the likelihood of non-response bias minimal?	Were data collected directly from the subjects?	Was an acceptable case definition used?	Was the study instrument reliable?	Was the same mode of data collection used for all subjects?	Score
Attwell	No	No	No	Yes	Yes	Yes	Yes	Yes	1
Seale	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Dietze	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Enticott	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Schernhammer	Yes	No	No	Yes	Yes	Yes	Yes	Yes	2
Kessels	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Lavoie	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Basta	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Abramovich	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Manca	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Bagic	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Neumann-Böhme	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Detoc	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	1
Ward	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Montagni	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Ousseine	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Coulaud	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Heyerdahl	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Bendau	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Kourlaba	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Murphy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Maor	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	1
Caserotti	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
La Vecchia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Di Giuseppe	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Moscardino	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Palamenghi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Iacoella	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Yoda	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Ihshimaru	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0

Machida	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Kadoya	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sekizawa	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Soares	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Khaled	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Page	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Freeman	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sethi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Freeman	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Batty	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Chaudhuri	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sherman	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sherman	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Earnshaw	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	1
Fisher	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Malik	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	1
Reiter	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	1
Pogue	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	1
Craig	Yes	Yes	No	No	Yes	Yes	Yes	Yes	1
Kelly	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Christodoulou	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Sullivan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Stern	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Rogers	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Crozier	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Thunström	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Rane	Yes	Yes	No	No	Yes	Yes	Yes	Yes	2
Scott	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Bogart	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Tucker	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Shaw	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0
Meehan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	0

3. Supplementary section 3: Table S2.Country-specific real-world data

Country	Population	% of population over 65 years	Life expectancy	Date of first vaccine	% of population with complete vaccination as of 31st 2021	Poverty gap	Gender wage gap	% unemployment	% unemployment in migrants	Social spending, %of GDP 2021	Healthcare spending, %GDP	Healthcare coverage	Stringency index at the date of first vaccine
Australia	25690000	16	83.2	22-Feb-21	74								53.24
Austria	8956000	19	81.8	27-Dec-20	71	0.294	14.9	4.9	8.3	31	10.3	99.9	82.41
Belgium	11590000	19	81.7	28-Dec-20	76	0.233	3.4	5.7	10.4	29	10.3	98.6	60.19
Canada	38250000	18	82.0	14-Dec-20	76	0.303	18.5	6.5	6.3	18	10.8	100	72.69
Croatia	3900000	22	77.7	27-Dec-20	49								67.59
Denmark	5857000	20	81.2	27-Dec-20	77	0.289	4.9	5.1	8.4	28.3	10.1	100	51.85
France	67750000	21	82.6	27-Dec-20	73	0.261	11.8	7.9	13.1	33	11.3	100	63.89
Germany	83000000	22	80.9	26-Dec-20	71	0.256	13.9	3.2	5.6	28	11.4	89.5	82.41
Greece	10640000	23	81.9	27-Dec-20	68	0.331	5.9	13.3	28.6	26	7.8	100	84.26
Ireland	5000000	15	82.3	29-Dec-20	77	0.187	8.3	5.1	5.9	14	6.7	100	68.52
Israel	9364000	12	82.8	19-Dec-20	63	0.325	22.7	5	3.4	18	7.5	100	71.3
Italy	59110000	24	83.2	27-Dec-20	76	0.396	5.7	9	13.1	31	8.7	100	78.7
Japan	126000000	30	84.4	17-Feb-21	80	0.364	24.5	2.8	4.2	22.3	10.7	100	49.54
Portugal	10330000	23	80.9	27-Dec-20	83	0.266	22.7	5.9	8.4	25	9.4	100	63.89
Qatar	2660000	1	79.1	31-Jan-21	82								64.81
Switzerland	8703000	19	83.7	23-Dec-20	67	0.281	18	2.6	7,3	18	11.9	100	60.19
UK	67330000	18	81.2	08-Dec-20	70	0.326	16.3	3.9	4.3	22	10.2	100	63.89
USA	332000000	17	77.2	14-Dec-20	63	0.368	18.9	8.09	3.1	23	16.9	91.4	71.76

4. Supplementary section 4: Country-specific analyses

Random-effects meta-analysis of COVID-19 vaccine acceptance in Australia

a. All the studies from Australia



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from Australia according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is

centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in Canada

a. All the studies from Canada



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from Canada according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in France

a. All the studies from France



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from France according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in Italy

a. All the studies from Italy



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from Italy according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in Japan



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in the United Kingdom



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

Random-effects meta-analysis of COVID-19 vaccine acceptance in the United States

a. All the studies from the U.S



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

b. Subgroup analysis from the U.S according to vaccine acceptance in the general population and among special populations



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

5. Supplementary section 5: Comparison between data from studies and real-world data

a. Table S3. Willingness to be vaccinated and real-world vaccine uptake

Country	% (CI 95%) of the general population willing to be vaccinated before vaccines rollout*	% (CI 95%) of special populations willing to be vaccinated before vaccines rollout*	% of the general population with complete vaccination as of 31st Dec 2021**	Difference between willingness and uptake
Australia	70 (58-79)	48 (27-70)	74	+4
Austria	36 (33-39)	-	71	+35
Belgium	34 (32-36)	-	76	+42
Canada	73 (42-91)	64 (32-87)	76	+3
Croatia	64 (60-67)		49	-15
Denmark	80 (79-81)	-	77	-3
France	69 (59-77)	61 (37-80)	73	+4
Germany	64 (62-67)	-	71	+7
Greece	58 (55-61)	-	68	+10
Ireland	65 (62-68)	-	77	+12
Israel	76 (74-78)	-	63	+7
Italy	67 (55-77)	64 (46-78)	76	+9
Japan	55 (42-67)	-	80	+25
Portugal	35 (33-37)	-	83	+48
Qatar	43 (40-45)		82	+39
Switzerland	-	41	67	-
UK	75 (63-84)	-	70	+5
USA	71 (63-78)	50 (39-61)	63	-8

*From the results of the systematic review.
**https://ourworldindata.org

b. Consolidated country data from studies and country real-world statistics





6. Supplementary section 6: Sensitivity analyses

a. Outlier and influential case diagnostics



rstudent= externally standardized residuals, dffits= difference in fit values, cook.de=Cook's distances, cov.r= covariance ratios, tau2.del= leave-one-out estimates of the amount of heterogeneity, QE.del= leave-one-out values of the test statistics for heterogeneity, hat= hat values, weight= weights

b. Cumulative meta-analysis of willingness to be vaccinated according to the date of data acquisition. General population.



c. Cumulative meta-analysis of willingness to be vaccinated according to the date of data acquisition. Special populations.



d. Cumulative real-world data meta-analysis according to the date of first COVID-19 vaccine administered in each country



e. Results from the generalized linear models for vaccine uptake and country-level data

	B	Standard error	p-value	OR	95% CI
Intercept	80.683	10.35	.000		
Stringency index	-.206	.10	.04	.81	(0.69-0.94)
% of the population older than 65 years	.595	.28	.03	1.8	(1.04-3.1)
Healthcare spending as % of GDP	-.997	.46	.03	0.36	(0.14-0.91)
Social spending as % of GDP	.183	.21	.4	1.2	(0.78-1.84)

f. Bubble plots from meta-regressiosn analyses to explore associations of country-level data with vaccine uptake

Stringency index



Percentage of the population older than 65 years



Healthcare spending as a percentage of GDP



g. Random-effects meta-analysis of COVID-19 vaccine acceptance in the general population for studies with high risk of selection bias



For each study, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% confidence interval. The size of each box is proportional to the weight of that study result in the fixed effect model. The red diamond represents the 95% confidence interval of the summary pooled estimate of the effect and is centred on pooled prevalence of vaccine acceptance. Heterogeneity estimate of I^2 accompanies the summary estimate. Studies are ordered by the proportion of acceptance CI = confidence interval.

7. Supplementary section. Checklists.

Prisma 2020 Checklist

Abstract checklist	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Yes
Synthesis of results	6	Specify the methods used to present and synthesise results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	No
Registration	12	Provide the register name and registration number.	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1, title
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Abstract
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Methods section, pages 5,6
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Supplementary section 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplementary section 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary section 1|
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Supplementary section 1
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Methods section, page 6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Supplementary section 1
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary section 1
Effect	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of	Data

Section and Topic	Item #	Checklist item	Location where item is reported
measures		results.	synthesis, page 7
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Data synthesis, page 7
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Sensitivity analyses, page 8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Sensitivity analyses, page 8
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	NA
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure S1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Supplementary material, section 1c
Study characteristics	17	Cite each included study and present its characteristics.	Results section, page 8 and Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table S1
Results of	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect	Figure 1,

Section and Topic	Item #	Checklist item	Location where item is reported
individual studies		estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 2.
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Supplementary section 3,
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Results section, pages 8-11
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Results section, page 10. Supplementary section 6
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Supplementary section 6
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Main findings, page 11
	23b	Discuss any limitations of the evidence included in the review.	Study limitations, page 13
	23c	Discuss any limitations of the review processes used.	-
	23d	Discuss implications of the results for practice, policy, and future research.	Findings in context, page 13
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	The review was not registered because it was a realist review

Section and Topic	Item #	Checklist item	Location where item is reported
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 1
Competing interests	26	Declare any competing interests of review authors.	Page 1
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Supplementary material

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
For more information, visit: http://www.prisma-statement.org/

RAMESES II reporting standards for realist evaluations:

Title: Realist review of COVID-19 vaccine acceptance in the general population and marginalized communities from high income countries

		Reported in document Y/N/ Not applicable	Page no.	Comment
1	**TITLE** In the title, identify the document as a realist evaluation	Yes (refers to it as realist review)	Title	In the title, reference is made to "realist review"
SUMMARY OR ABSTRACT				
2	Journal articles will usually require an abstract, while reports and other forms of publication will usually benefit from a short summary. The abstract or summary should include brief details on: the policy, programme or initiative under evaluation; programme setting; purpose of the evaluation; evaluation question(s) and/or objective(s); evaluation strategy; data collection, documentation and analysis methods; key findings and conclusions. Where journals require it and the nature of the study is appropriate, brief details of respondents to the evaluation and recruitment and sampling processes may also be included. Sufficient detail should be provided to identify that a realist approach was used and that realist programme theory was developed and/or refined	Yes	Abstract	

			Reported in document Y/N/Not applicable	Page(s) in document	Comment
INTRODUCTION					
3	Rationale for evaluation	Explain the purpose of the evaluation and the implications for its focus and design	Yes	P. 4	
4	Programme theory	Describe the initial programme theory (or theories) that underpin the programme, policy or initiative	Yes	P. 4	
5	Evaluation questions, objectives and focus	State the evaluation question(s) and specify the objectives for the evaluation. Describe whether and how the programme theory was used to define the scope and focus of the evaluation	Yes	P. 4	
6	Ethical approval	State whether the realist evaluation required and has gained ethical approval from the relevant authorities, providing details as appropriate. If ethical approval was deemed unnecessary, explain why	Not applicable	-	No original data collected

			Reported in document Y/N/ Not applicable	Page(s) in document	Comment
METHODS					
7	Rationale for using realist evaluation	Explain why a realist evaluation approach was chosen and (if relevant) adapted	Yes	P. 4	
8	Environment surrounding the evaluation	Describe the environment in which the evaluation took place	Yes	Title	Title locates the study to high income countries.
9	Describe the programme policy, initiative or product evaluated	Provide relevant details on the programme, policy or initiative evaluated	Yes	Title p. 5	Title refers to COVID-19 vaccine acceptance
10	Describe and justify the evaluation design	A description and justification of the evaluation design should be included, at least in summary form or as an appendix, in the document which presents the main findings. If this is not done, the omission should be justified and a reference or link to the evaluation design given. It may also be useful to publish or make freely available any original evaluation design document or protocol, where they exist	Yes		
11	Data collection methods	Describe and justify the data collection methods – which ones were used, why and how they fed into developing, supporting, refuting or refining programme theory	Yes	S1	Supplementary section 1

		Provide details of the steps taken to enhance the trustworthiness of data collection and documentation	Yes	S1	Supplementary section 1
12	Recruitment process and sampling strategy	Describe how respondents to the evaluation were recruited or engaged and how the sample contributed to the development, support, refutation or refinement of programme theory	Yes	p. 5,6	No original empirical study but review of other studies Methods section describes inclusion and exclusion criteria Supplementary section 1 provides more details on databases and screening process
13	Data analysis	Describe in detail how data were analysed. This section should include information on the constructs that were identified, the process of analysis, how the programme theory was further developed, supported, refuted and refined, and (where relevant) how analysis changed as the evaluation unfolded	Yes	p. 7 p. 8	Data synthesis Sensitivity analyses, page 8

			Reported in document Y/N/Unclear/ Not applicable	Page(s) in document	Comment
RESULTS					
14	Details of participants	Report (if applicable) who took part in the evaluation, the details of the data they provided and how the data was used to develop, support, refute or refine programme theory	Yes	S1	Supplementary section 1
15	Main findings	Present the key findings, linking them to contexts, mechanisms and outcome configurations. Show how they were used to further develop, test or refine the programme theory	Yes	P. 8	Results section, and Table 1
DISCUSSION					
16	Summary of findings	Summarise the main findings with attention to the evaluation questions, purpose of the evaluation, programme theory and intended audience	Yes	P. 8-11	Figures 1 and 2 Results section,

			Reported in document Y/N/Unclear/ Not applicable	Page(s) in document	Comment
17	Strengths, limitations and future directions	Discuss both the strengths of the evaluation and its limitations. These should include (but need not be limited to): (1) consideration of all the steps in the evaluation processes; and (2) comment on the adequacy, trustworthiness and value of the explanatory insights which emerged In many evaluations, there will be an expectation to provide guidance on future directions for the programme, policy or initiative, its implementation and/or design. The particular implications arising from the realist nature of the findings should be reflected in these discussions	Yes	p. 13	

TITLE			Reported in document Y/N/Unclear/ Not applicable	Page(s) in document	Comment
18	Comparison with existing literature	Where appropriate, compare and contrast the evaluation's findings with the existing literature on similar programmes, policies or initiatives	Yes	P. 11	Main findings
19	Conclusion and recommendations	List the main conclusions that are justified by the analyses of the data. If appropriate, offer recommendations consistent with a realist approach	Yes	p. 13	Cf. "Findings in context" in the manuscript
20	Funding and conflict of interest	State the funding source (if any) for the evaluation, the role played by the funder (if any) and any conflicts of interests of the evaluators	Yes	P. 1	

Adapted from table 1 in:
Wong G, Westhorp G, Manzano A, *et al*. RAMESES II reporting standards for realist evaluations. *BMC Med* 2016; 14:96.

Prisma 2020 Checklists

Abstract checklist	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Yes
Synthesis of results	6	Specify the methods used to present and synthesise results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	No
Registration	12	Provide the register name and registration number.	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1, title
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Abstract
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Methods section, pages 5,6
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Supplementary section 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplementary section 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary section 1|
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Supplementary section 1
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Methods section, page 6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Supplementary section 1
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Supplementary section 1
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Data synthesis, page 7
Synthesis	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics	

Section and Topic	Item #	Checklist item	Location where item is reported
methods		and comparing against the planned groups for each synthesis (item #5)).	
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Data synthesis, page 7
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Sensitivity analyses, page 8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Sensitivity analyses, page 8
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	NA
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure S1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Supplementary material, section 1c
Study characteristics	17	Cite each included study and present its characteristics.	Results section, page 8 and Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table S1
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 1, Figure 2.
Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Supplementary

Section and Topic	Item #	Checklist item	Location where item is reported
syntheses			section 3,
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Results section, pages 8-11
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Results section, page 10. Supplementary section 6
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Supplementary section 6
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Main findings, page 11
	23b	Discuss any limitations of the evidence included in the review.	Study limitations, page 13
	23c	Discuss any limitations of the review processes used.	-
	23d	Discuss implications of the results for practice, policy, and future research.	Findings in context, page 13
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	The review was not registered because it was a realist review
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA

Section and Topic	Item #	Checklist item	Location where item is reported
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 1
Competing interests	26	Declare any competing interests of review authors.	Page 1
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Supplementary material

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
For more information, visit: http://www.prisma-statement.org/

RAMESES II reporting standards for realist evaluations:

Title: Realist review of COVID-19 vaccine acceptance in the general population and marginalized communities from high income countries

		Reported in document Y/N/ Not applicable	Page no.	Comment
1	**TITLE** In the title, identify the document as a realist evaluation	Yes (refers to it as realist review)	Title	In the title, reference is made to "realist review"
SUMMARY OR ABSTRACT				
2	Journal articles will usually require an abstract, while reports and other forms of publication will usually benefit from a short summary. The abstract or summary should include brief details on: the policy, programme or initiative under evaluation; programme setting; purpose of the evaluation; evaluation question(s) and/or objective(s); evaluation strategy; data collection, documentation and analysis methods; key findings and conclusions. Where journals require it and the nature of the study is appropriate, brief details of respondents to the evaluation and recruitment and sampling processes may also be included. Sufficient detail should be provided to identify that a realist approach was used and that realist programme theory was developed and/or refined	Yes	Abstract	

			Reported in document Y/N/Not applicable	Page(s) in document	Comment
INTRODUCTION					
3	Rationale for evaluation	Explain the purpose of the evaluation and the implications for its focus and design	Yes	P. 4	
4	Programme theory	Describe the initial programme theory (or theories) that underpin the programme, policy or initiative	Yes	P. 4	
5	Evaluation questions, objectives and focus	State the evaluation question(s) and specify the objectives for the evaluation. Describe whether and how the programme theory was used to define the scope and focus of the evaluation	Yes	P. 4	
6	Ethical approval	State whether the realist evaluation required and has gained ethical approval from the relevant authorities, providing details as appropriate. If ethical approval was deemed unnecessary, explain why	Not applicable	-	No original data collected

			Reported in document Y/N/ Not applicable	Page(s) in document	Comment
METHODS					
7	Rationale for using realist evaluation	Explain why a realist evaluation approach was chosen and (if relevant) adapted	Yes	P. 4	
8	Environment surrounding the evaluation	Describe the environment in which the evaluation took place	Yes	Title	Title locates the study to high income countries.
9	Describe the programme policy, initiative or product evaluated	Provide relevant details on the programme, policy or initiative evaluated	Yes	Title p. 5	Title refers to COVID-19 vaccine acceptance
10	Describe and justify the evaluation design	A description and justification of the evaluation design should be included, at least in summary form or as an appendix, in the document which presents the main findings. If this is not done, the omission should be justified and a reference or link to the evaluation design given. It may also be useful to publish or make freely available any original evaluation design document or protocol, where they exist	Yes		
11	Data collection methods	Describe and justify the data collection methods – which ones were used, why and how they fed into developing, supporting, refuting or refining programme theory	Yes	S1	Supplementary section 1

		Provide details of the steps taken to enhance the trustworthiness of data collection and documentation	Yes	S1	Supplementary section 1
12	Recruitment process and sampling strategy	Describe how respondents to the evaluation were recruited or engaged and how the sample contributed to the development, support, refutation or refinement of programme theory	Yes	p. 5,6	No original empirical study but review of other studies Methods section describes inclusion and exclusion criteria Supplementary section 1 provides more details on databases and screening process
13	Data analysis	Describe in detail how data were analysed. This section should include information on the constructs that were identified, the process of analysis, how the programme theory was further developed, supported, refuted and refined, and (where relevant) how analysis changed as the evaluation unfolded	Yes	p. 7 p. 8	Data synthesis Sensitivity analyses, page 8

			Reported in document Y/N/Unclear/ Not applicable	Page(s) in document	Comment
RESULTS					
14	Details of participants	Report (if applicable) who took part in the evaluation, the details of the data they provided and how the data was used to develop, support, refute or refine programme theory	Yes	S1	Supplementary section 1
15	Main findings	Present the key findings, linking them to contexts, mechanisms and outcome configurations. Show how they were used to further develop, test or refine the programme theory	Yes	P. 8	Results section, and Table 1
DISCUSSION					
16	Summary of findings	Summarise the main findings with attention to the evaluation questions, purpose of the evaluation, programme theory and intended audience	Yes	P. 8-11	Figures 1 and 2 Results section,

			Reported in document Y/N/Unclear/ Not applicable	Page(s) in document	Comment
17	Strengths, limitations and future directions	Discuss both the strengths of the evaluation and its limitations. These should include (but need not be limited to): (1) consideration of all the steps in the evaluation processes; and (2) comment on the adequacy, trustworthiness and value of the explanatory insights which emerged In many evaluations, there will be an expectation to provide guidance on future directions for the programme, policy or initiative, its implementation and/or design. The particular implications arising from the realist nature of the findings should be reflected in these discussions	Yes	p. 13	

TITLE			Reported in document Y/N/Unclear/ Not applicable	Page(s) in document	Comment
18	Comparison with existing literature	Where appropriate, compare and contrast the evaluation's findings with the existing literature on similar programmes, policies or initiatives	Yes	P. 11	Main findings
19	Conclusion and recommendations	List the main conclusions that are justified by the analyses of the data. If appropriate, offer recommendations consistent with a realist approach	Yes	p. 13	Cf. "Findings in context" in the manuscript
20	Funding and conflict of interest	State the funding source (if any) for the evaluation, the role played by the funder (if any) and any conflicts of interests of the evaluators	Yes	P. 1	

Adapted from table 1 in:
Wong G, Westhorp G, Manzano A, *et al*. RAMESES II reporting standards for realist evaluations. *BMC Med* 2016; 14:96.